Document:

Exhibit 10.32

 

 

AMENDED and RESTATED

 

OPERATING AGREEMENT

 

of

 

BIOLOGISTEX CCM,
LLC

 

Dated as of December
31, 2016

 

 

     

     

    

 

TABLE OF CONTENTS

 

	ARTICLE
    I DEFINITIONS	2
	 	 
	ARTICLE II THE COMPANY
    AND ITS BUSINESS	9
	 	 
	ARTICLE III MEMBERS	10
	 	 
	ARTICLE IV RIGHTS,
    DUTIES AND POWERS OF MANAGEMENT COMMITTEE AND MEMBERS	12
	 	 
	ARTICLE V OFFICERS	22
	 	 
	ARTICLE VI INTELLECTUAL
    PROPERTY	23
	 	 
	ARTICLE VII TRANSFERS
    OF MEMBERSHIP INTERESTS	24
	 	 
	ARTICLE VIII PROFITS,
    LOSSES AND DISTRIBUTIONS	26
	 	 
	ARTICLE IX DISSOLUTION
    AND LIQUIDATION	30
	 	 
	ARTICLE X NO REQUIREMENT
    TO RESTORE DEFICIT IN CAPITAL ACCOUNT	31
	 	 
	ARTICLE XI BOOKS,
    RECORDS AND EXPENSES	31
	 	 
	ARTICLE XII AMENDMENTS	32
	 	 
	ARTICLE XIII GENERAL
    PROVISIONS	32

 

SCHEDULES

 

	Schedule A	Members and Capital Contributions
	 	 
	Schedule B	List of the BioLife Copyrights
	 	 
	Schedule C	List of the Savsu Patents

 

    	 	i	 

     

    

 

AMENDED and RESTATED OPERATING AGREEMENT

 

OF

 

BIOLOGISTEX CCM, LLC

 

This AMENDED and RESTATED
OPERATING AGREEMENT (“Agreement”) of BIOLOGISTEX CCM, LLC (“Company”) dated as of December 31,
2016 (“Effective Date”) by and among the Company, BIOLIFE SOLUTIONS, INC., with a principal place of business
at 3303 Monte Villa Parkway, Suite 310, Bothell, Washington 98021 (“BioLife”), SAVSU TECHNOLOGIES, LLC, with
a principal place of business at 160 Sweet Hollow Road, Old Bethpage, New York 11804 (“Savsu”) and such other
parties, if any, who have executed the signature page(s) hereto as members of the Company and whose names and addresses appear
on Schedule A hereto (BioLife, Savsu and such other parties are each sometimes referred to herein as a “Member”
and collectively, the “Members”).

 

WHEREAS, the
Company was formed as a Delaware limited liability company upon the filing of a certificate of formation (the “Certificate
of Formation”) on September 29, 2014 in the offices of the Secretary of State of Delaware;

 

WHEREAS, the
Members entered into an undated Limited Liability Company Agreement of the Company (the “LLC Agreement”). This
Agreement amends and restates the LLC Agreement in its entirety;

 

WHEREAS, in
connection with the amendment and restatement of this Agreement, Savsu shall contribute certain machinery, equipment, inventory
and IP to the Company, in the agreed-upon value set forth at Schedule A;

 

WHEREAS, Biolife
held indebtedness of the Company, which indebtedness has been contributed by Biolife to the capital of the Company during 2016
in exchange for additional equity in the Company;

 

WHEREAS, the
parties hereto have agreed to enter into this Agreement to provide for their rights, obligations and responsibilities as holders
of Membership Interests.

 

NOW, THEREFORE,
in consideration of the mutual promises, covenants and undertakings of the parties hereto, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as of the Effective Date as follows:

 

    	 	1	 

     

    

 

ARTICLE I

DEFINITIONS

 

1.1         Definitions.
As used in this Agreement and the Exhibits, Schedules and Annexes hereto, the following terms shall have the meanings set forth
below:

 

“Act”
shall mean the Delaware Limited Liability Company Act, 6 Del. C. § 18101 et seq., and any successor statute
thereto, as amended from time to time.

 

“Adjusted Capital
Account” means, with respect to any Member, at any time, the Member’s Capital Account at such time (a) increased
by the sum of (i) the amount of such Member’s share of “partnership minimum gain” (as defined in Treas. Reg.
§ 1.704-2(g)(1) and (3)), (ii) the amount of such Member’s share of “partner nonrecourse debt minimum gain”
(as defined in Treas. Reg. § 1.704-2(i)(5)), and (iii) any amount of the deficit balance in such Member’s Capital Account
that the Member is obligated to restore on liquidation of the Company and (b) decreased by reasonably expected adjustments, allocations,
and distributions described in Treas. Reg. §§ 1.704-1(b)(2)(ii)(d)(4), (5), or (6). The foregoing definition
of Adjusted Capital Account is intended to comply with the provisions of Treas. Reg. § 1.704-1(b)(2)(ii)(d) and shall
be interpreted and applied in a manner consistent therewith.

 

The foregoing definition
of “Adjusted Capital Account Deficit” is intended to comply with the provisions of Treasury Regulations Sections 1.704-1(b)(2)(ii)(d)
and 1.704-2, and shall be interpreted consistently therewith.

 

“Affiliate”
shall mean with respect to any Person (i) any other Person that directly or indirectly through one or more intermediaries controls
or is controlled by or is under common control with such Person, (ii) any other Person owning or controlling 10% or more of the
outstanding voting securities of, or other ownership interests in, such Person, (iii) any officer, director or member of such
Person, (iv) if such Person is an officer, director or member of the company for which such Person acts in any such capacity and
(v) in the case of an individual, any Relative of such individual. For purposes of this definition, “control,”
when used with respect to any Person, means the power to direct the management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise, and the terms “controlling” and
“controlled” have meanings correlative to the foregoing.

 

“Agreement”
shall mean this Amended and Restated Operating Agreement, as it may hereafter be amended or modified from time to time.

 

“Annual Financial
Statements” shall have the meaning set forth in Section 4.5(c).

 

“Assignee”
shall mean the transferee pursuant to this Agreement of a Member’s Membership Interest, who or which has not been admitted
as a Substituted Member.

 

“Available
Cash” shall mean the cash reserves of the Company in excess of that required to satisfy existing liabilities and to
provide for future contingencies or future needs of the business of the Company, as determined from time to time by the Management
Committee.

 

    	 	2	 

     

    

 

“Bankruptcy
Event” shall mean, with respect to any Person:

 

(i)          the
adjudication that such Person is bankrupt or insolvent, or the entry of a final and non-appealable order for relief under Title
11 of the United States Code or any other applicable federal or state bankruptcy or insolvency law;

 

(ii)         the
admission by such Person of its inability to pay its debts as they mature;

 

(iii)        the
making by such Person of an assignment for the benefit of creditors;

 

(iv)        the
filing by such party of a petition in bankruptcy or a petition for relief under Title 11 of the United States Code or any other
applicable federal or state bankruptcy or insolvency law;

 

(v)         the
expiration of sixty (60) days after the filing of an involuntary petition under Title 11 of the United States Code, an application
for the appointment of a receiver for the assets of such Person, or an involuntary petition seeking liquidation, reorganization,
arrangement or readjustment of its debts under any other federal or state insolvency law; provided, that the same shall
not have been vacated, set aside or stayed within such sixty (60) day period;

 

(vi)        the
imposition of a judicial or statutory lien on all or a substantial part of such Person’s assets unless such lien is discharged
or vacated or the enforcement thereof stayed within sixty (60) days after its effective date; and

 

(vii)       the
filing by such Person of an answer or other pleading admitting or failing to contest the material allegations of a petition filed
against it in any proceeding of the nature described in clause (v) above, and

 

(viii)      the
expiration of sixty (60) days after the commencement of any stay referred to in clause (v) or (vi) above; provided, that
the subject of such stay shall not have been vacated or set aside within such sixty (60) day period.

 

“BioLife Copyrights”
shall mean the copyrights and copyright registrations as set forth on Schedule B hereto.

 

“Book Value”
with respect to any assets of the Company shall mean its adjusted basis for federal income tax purposes, except that (i) the initial
Book Value of any asset contributed by a Member to the Company shall be an amount equal to the fair market value of such asset,
as determined by the Management Committee, (ii) the Book Value of any Company asset distributed to any Member shall be the fair
market value of such asset on the date of distribution as determined by the Management Committee, and (iii) such Book Value shall
thereafter be adjusted in a manner consistent with Treasury Regulations Section 1.704-l(b)(2)(iv)(g) and for the Depreciation
taken into account with respect to such asset.

 

    	 	3	 

     

    

 

“Business”
shall mean the business of transporting and storing temperature sensitive vaccines and new “live cell” medical treatments.

 

“Business Day”
shall mean any day other than a Saturday, Sunday or any other day on which banks in New York are required or permitted to be closed.

 

“Capital Account”
shall mean the capital account established and maintained on the books of the Company for each Member in accordance with the provisions
of Treasury Regulation Section l.704-1(b)(2)(iv) as shall be adjusted upon the occurrence of certain events as provided in Treasury
Regulation Section 1.704-1(b)(2)(iv)(f). Such Capital Account balance shall be (i) reduced from time to time by (A) the amount
of money or agreed net fair market value of any property distributions from the Company to such Member pursuant to this Agreement
(net of liabilities secured by such distributed property that such Member is considered to assume or take subject to under Section
752 of the Code) and (B) the amount of any Losses allocated to such Member under Section 8.3 and (C) any and all indebtedness
of the Company to the Member to the extent they are repaid, (ii) increased from time to time by (A) the amount of any Profits
allocable to such Member under Section 8.3 and (B) the amount of money or agreed net fair market value of any property
contributed by such Member (net of liabilities secured by such contributed property that the Company is considered to assume or
take subject to under Section 752 of the Code), and (C) any and all indebtedness of the Company to the Member to the extent they
are incurred, and (iii) otherwise adjusted as required under Section 1.704-1(b)(2)(iv) of the Treasury Regulations. In the event
of a Transfer of some or all of a Membership Interest, the Capital Account of the assignor shall become the Capital Account of
the Assignee or the Substituted Member, as the case may be, to the extent it relates to the portion of the Membership Interest
Transferred. In connection with the contribution by Savsu, the Company shall revalue the assets of the Company and shall allocate
unrealized Profits or Losses in a manner consistent with Sections 8.3(c) and (d) as if there were a Liquidity Event.

 

“Capital Contribution”
shall mean any cash, property, services rendered, or a promissory note or other binding obligation to contribute cash or property
or to render services that a Member contributes to the Company in the capacity of a Member.

 

“Capital Percentage(s)”
shall mean a Member’s share of the Company’s Profits from such Liquidity Event as set forth below:

 

(a)          For
a Liquidity Event that is consummated prior to the first (1st) anniversary of the Effective Date, the Capital Percentages
of the Members shall be forty-five (45%) percent to BioLife and fifty-five (55%) percent to Savsu;

 

(b)          For
a Liquidity Event that is consummated on or after the first (1st) anniversary of the Effective Date and prior to the
second (2nd) anniversary of the Effective Date, the Capital Percentages of the Members shall be forty (40%) percent
to BioLife and sixty (60%) percent to Savsu;

 

(c)          For
a Liquidity Event that is consummated on or after the second (2nd) anniversary of the Effective Date and prior to the
third (3rd) anniversary of the Effective Date, the Capital Percentages of the Members shall be thirty-five (35%) percent
to BioLife and sixty-five (65%) percent to Savsu; and

 

    	 	4	 

     

    

 

(d)          For
a Liquidity Event that is consummated on or after the third (3rd) anniversary of the Effective Date, the Capital Percentages
of the Members shall be twenty-five (25%) percent to BioLife and seventy-five (75%) percent to Savsu.

 

“Certificate
of Formation” shall have the meaning set forth in the Recitals.

 

“Change in
Control” means any sale, transfer or issuance or series of sales, transfers and/or issuances of Membership Interests
which results in a majority of the Membership Interests of the Company no longer being owned by the Members owning such Membership
Interests immediately prior to the transaction in question.

 

“Code”
shall mean the Internal Revenue Code of 1986, as amended and in effect from time to time, or any corresponding provision(s) of
succeeding law.

 

“Confidential
Information” has the meaning set forth in Section 4.10.

 

“Deemed Sale”
shall have the meaning set forth in Section 7.2.

 

“Depreciation”
shall mean, with respect to any Fiscal Year, all deductions attributable to depreciation or cost recovery with respect to assets
of the Company, including any improvements made thereto and any tangible personal property located therein, or amortization of
the cost of any intangible property or other assets acquired by the Company, which have a useful life exceeding one year, provided,
however, that with respect to any asset of the Company whose tax basis differs from its Book Value at the beginning of
such Fiscal Year or other period, Depreciation shall be an amount which bears the same ratio to such beginning Book Value as the
depreciation, amortization or other cost recovery deduction for such period with respect to such asset for federal income tax
purposes bears to its adjusted tax basis as of the beginning of such Fiscal Year; provided, however, that if the
federal income tax depreciation, amortization or other cost recovery deduction for such Fiscal Year is zero, Depreciation shall
be determined using any reasonable method selected by the Management Committee.

 

“Distributed
Royalties” shall mean the aggregate amount of Distributions of Royalties by the Company to Biolife pursuant to Section
8.1(a).

 

“Distribution”
shall mean the transfer of property by the Company to one or more of its Members in the capacity of a Member.

 

“Drag-Along
Option” shall have the meaning set forth in Section 7.3.

 

“Exculpated
Parties” shall have the meaning set forth in Section 4.4(b).

 

“Fiscal Year”
shall mean the fiscal year of the Company, which shall be the calendar year; but upon termination of the Company, “Fiscal
Year” shall mean the period from the end of the last preceding Fiscal Year to the date of such termination.

 

    	 	5	 

     

    

 

“FMV”
shall mean fair market value as determined by the Management Committee in its sole discretion or, if such Management Committee
cannot agree, by an independent appraiser selected by the Management Committee.

 

“GAAP”
shall mean United States generally accepted accounting principles in effect from time to time, using the accounting methods, practices,
principles, policies and procedures, with consistent classifications, judgments and valuation and estimation methodologies that
were used in the preparation of the Annual Financial Statements.

 

“Governmental
Authority” shall mean any governmental, administrative or regulatory agency, bureau, department or other body, whether
federal, state, local or foreign.

 

“Indemnified
Parties” shall have the meaning set forth in Section 4.4(a).

 

“Initial Managers”
shall mean Michael Rice, Dana Barnard and Bruce McCormick.

 

“Inventions”
shall mean all original works of authorship, software applications, computer code, inventions, ideas, discoveries, improvements,
modifications, writings, artistic or creative material, and other intellectual property in any form whatsoever (whether or not
patented and/or copyrighted).

 

“Liquidity
Event” shall mean the consummation of a transaction or series of related transactions pursuant to which the Company
shall sell its business or substantially all of its assets or Membership Interests, borrow money or enter into a financing transaction
in which the assets of the Company are mortgaged or pledged (excluding customary liabilities in the Company’s ordinary course
of business), or merge or consolidate with another Person, or recapitalize, split up and/or combine the existing Membership Interests
of the Company other than in connection with the consummation of a New Investment Round, or consummate an initial public offering
of the Company’s securities, or any other transaction that results in a Change in Control.

 

“Majority Purchaser”
shall have the meaning set forth in Section 7.3.

 

“Management
Committee” shall have the meaning set forth in Section 4.1.

 

“Managers”
shall mean the Initial Managers and such other Persons as may be appointed as Managers in accordance with Section 4.2.

 

“Member”
shall mean each of those persons listed on Schedule A hereto (as such Schedule A may be amended from time to time),
their successors and permitted assigns and any other members admitted to the Company in accordance with this Agreement.

 

“Membership
Interest(s)” shall mean a Member’s aggregate rights in the Company, including but not limited to such Member’s
right to the share of the Profits and Losses of the Company, the right to receive Distributions from the Company, and the right
to vote its Membership Interests to the extent provided herein.

 

“Negative Capital
Account” shall have the meaning set forth in Section 3.9.

 

    	 	6	 

     

    

 

“Net Profits”
and “Net Losses” shall mean the sum of the Profits and Losses, defined below, for each taxable year of the
Company.

 

“New Investment
Round” shall mean one or more capital investment(s) in the Company subsequent to the Effective Date by a Person that
may include Savsu but is otherwise not a Member of the Company as of the date of such investment, in an aggregate sum of approximately
$5,000,000-$7,000,000, on terms and conditions acceptable to the Management Committee in its sole discretion.

 

“New Investor”
shall mean a Person who purchases Membership Interests from the Company in a New Investment Round.

 

“Non-Selling
Member(s)” shall have the meaning set forth in Section 7.3.

 

“Offer”
shall have the meaning set forth in Section 7.4.

 

“Officer”
shall have the meaning set forth in Section 5.1.

 

“Operations”
means any and all transactions of the Company, excluding Liquidity Events.

 

“Person”
shall mean any individual, partnership, corporation, limited liability company, trust or other legal entity.

 

“Preferred
Basis” the sum of the formula: (i) Preferred Capital minus (ii) aggregate Distributions pursuant to Sections 8.1(b)
and 8.2(b) plus aggregate Losses allocated pursuant to Section 8.3(b)(i).

 

“Preferred
Capital” the amount of the preferred capital contributed to the Company and so designated, as further set forth in Section
3.2.

 

“Preferred
Member” the Member or Members who or which hold Preferred Membership Interests.

 

“Preferred
Membership Interest” the preferred membership interest attributable to the contribution of preferred capital.

 

“Profits”
and “Losses” mean for each taxable year of the Company, the amount of the Company’s income and gain or
the Company’s losses and deductions, respectively, determined for federal income tax purposes, in accordance with Section
703(a) of the Code (including, without limitation, all items of income, gain, loss, or deduction required to be separately stated
pursuant to Section 703(a)(1) of the Code), with the following modifications:

 

		(a)	The amount determined
                                         above shall be increased by income exempt from federal income tax;

 

		(b)	The amount determined
                                         above shall be reduced by any expenditures described in Section 705(a)(2)(B) of the Code
                                         or expenditures treated as such pursuant to Treas. Reg. § 1.704-1(b)(2)(iv)(i);

 

    	 	7	 

     

    

 

		(c)	Depreciation,
                                         amortization and other cost recovery deductions shall be computed based on their respective
                                         book values in accordance with the provisions of Treas. Reg. §§ 1.704-1(b)(2)(iv)(g)(3)
                                         and 1.704-3(d)(2), as applicable;

 

		(d)	Gain or loss
                                         resulting from a disposition of property to which the principles of Section 704(c) of
                                         the Code apply shall be computed by reference to the book value of such property, notwithstanding
                                         that the adjusted tax basis of such property differs from its book value;

 

		(e)	Any book gain
                                         or book loss resulting from a revaluation of property attributable to unrealized gain
                                         or loss in such property shall be taken into account for purposes of computing Profits
                                         or Losses;

 

		(f)	Any items which
                                         are regulatory or special allocations under Section 8.7 shall not be taken into account
                                         in computing Profits or Losses.

 

“Profits Percentage(s)”
shall mean a Member’s share of the Company’s Profits and Losses as set forth below:

 

		(a)	During the period
                                         commencing on the Effective Date and ending on the first (1st) anniversary
                                         of the Effective Date, the Profits Percentages of the Members shall be forty-five (45%)
                                         percent to BioLife and fifty-five (55%) percent to Savsu;

 

		(b)	During the period
                                         subsequent to the first (1st) anniversary of the Effective Date and ending
                                         on the second (2nd) anniversary of the Effective Date, the Profits Percentages
                                         of the Members shall be forty (40%) percent to BioLife and sixty (60%) percent to Savsu;
                                         and

 

		(c)	Subsequent to
                                         the third (3rd) anniversary of the Effective Date, the Profits Percentages
                                         of the Members shall be twenty-five (25%) percent to BioLife and seventy-five (75%) percent
                                         to Savsu.

 

“Royalty”
shall mean the payments due to BioLife pursuant to the Services Agreement.

 

“Savsu Patents”
shall mean the patents and patent registrations set forth on Schedule C hereto.

 

    	 	8	 

     

    

 

“Services Agreement”
shall mean that certain Services Agreement between BioLife and the Company, dated the date hereof, as same may be amended from
time to time.

 

“Substituted
Member” shall mean an Assignee admitted as a Member of the Company in accordance with this Agreement.

 

“Supermajority”
means the Member(s) (which must include Savsu and BioLife) whose aggregate Membership Interest constitutes not less than sixty
(60%) percent of the aggregate outstanding Membership Interests of the Company.

 

“Supermajority
Interests” shall have the meaning set forth in Section 7.3.

 

“Tag-Along
Option” shall have the meaning set forth in Section 7.4.

 

“Transfer”
shall mean any sale, assignment, transfer, exchange, mortgage, pledge, grant, hypothecation, or other transfer, absolute or as
security or encumbrance (including dispositions by operation of law).

 

“Treasury Regulation(s)”
and “Treas. Reg.” shall mean the regulation or regulations promulgated by the United States Department of Treasury
under the Code, as such regulation or regulations are in effect on the date hereof and from time to time.

 

“Undistributed
Preferred Capital” the amount of a Preferred Member’s initial Preferred Capital reduced by aggregate amount of
Distributions pursuant to Sections 8.1(b) and 8.2(c).

 

1.2         Terms
Generally. For all purposes of this Agreement, except as otherwise expressly provided or unless the context otherwise requires:

 

(a)          the
terms defined in this Article have the meanings assigned to them in this Article and include both the plural and the singular;

 

(b)          the
words “hereto”, “herein,” “hereof” and “hereunder”
and other words of similar import refer to this Agreement as a whole and not to any particular Article, Section or other subdivision;
and

 

(c)          the
words “including” and “include” and other words of similar import shall be deemed to be
followed by the phrase “without limitation.”

 

ARTICLE II

THE COMPANY AND ITS BUSINESS

 

2.1         Formation.
The Company has been formed as a limited liability company under the Act. The parties hereto desire to set forth the duties and
obligations of the Members and the Management Committee of the Company in accordance with the terms and conditions set forth herein.

 

    	 	9	 

     

    

 

2.2           Place
of Business. The principal office of the Company shall be located at 160 Sweet Hollow Road, Old Bethpage, New York 11804,
or at such other place as the Management Committee may designate from time to time.

 

2.3           Term.
The term of the Company shall be effective on the date the Certificate of Formation was filed with the Secretary of State of the
State of Delaware, and shall continue to exist until it is dissolved or terminated under the terms of this Agreement or as provided
by law. The Company shall forthwith be terminated and dissolved and its business and affairs liquidated only upon the unanimous
vote of the Management Committee and each Member hereby waives its/his/her right to seek a court decree of dissolution or to seek
the appointment by a court of a liquidator for the Company.

 

2.4           Purpose;
Authority and Powers. The Company is formed to conduct and operate the Business and for any other lawful business purpose
or purposes, and, subject to the provisions of this Agreement, may exercise all of the powers provided in Section 18-106 of the
Act. Notwithstanding the foregoing, any change in the nature of the Business shall be subject to the provisions of Section
4.3.

 

ARTICLE III

MEMBERS

 

3.1           Capital
of the Company. The capital of the Company shall be the sum of the Members’ Capital Contributions. As of the Effective
Date, each Member’s Capital Account shall be as set forth opposite such Member’s name on Schedule A hereto
and shall be subject to subsequent adjustment as provided in this Agreement.

 

3.2           Additional
Capital Contributions. No Member shall be obligated to contribute any additional capital to the Company. In connection with
this amended and restated Agreement, Savsu has made certain additional capital contributions the value of which is stipulated
and agreed to as $__________ (“Preferred Capital”).

 

3.3           Withdrawal.
No Member shall have the right to withdraw from the Company except as expressly permitted by the terms of this Agreement. Any
attempt by a Member to withdraw from the Company in violation of this Agreement shall be ineffective. The Company shall have no
obligation to pay to any Member withdrawing from the Company in violation of this Section 3.3 the FMV for such Member’s
Membership Interest as of the date of withdrawal.

 

3.4           No
Interest. Members shall not be entitled to receive any interest on their Capital Contributions to the Company.

 

3.5           No
Return of Capital. Except as otherwise specifically provided in this Agreement, no Member shall be entitled to demand or receive
the return of its Capital Contributions.

 

    	 	10	 

     

    

 

3.6         Admission
of Additional Members. The Management Committee is authorized to admit one or more additional Members for such Capital Contributions
and upon such terms and conditions as they shall deem to be in the best interest of the Company. In the event any additional Members
are admitted to the Company pursuant to this Section 3.6, the Membership Interest in the Company of the then existing Members
(as shown on Schedule A) shall be reduced pro rata in an aggregate amount equal to the aggregate Membership
Interest in the Company acquired by the new Member(s). In connection with any such admission, the Management Committee may elect
to adjust the Capital Accounts of the Members to reflect the then current FMV of the assets of the Company pursuant to and in
accordance with Section 1.704-1(b)(2)(iv)(f) of the Treasury Regulations. To accomplish the purposes of this Section, the Management
Committee are authorized to do all things necessary to effectuate the admission of such additional Members (including the recomputation
and revision of Schedule A), each of whom shall become a signatory hereto upon executing a signature page, whereby each
such additional Member shall be deemed to have adopted and to have agreed to be bound by all of the provisions of this Agreement.
The original copy of this Agreement, and any duly executed signature pages, taken together, shall constitute a single instrument.

 

3.7         New
Investment Round.

 

(a)          New
Investor. The Management Committee is expressly authorized to offer, sell and issue Membership Interests to one or
more New Investors in a New Investment Round on such terms and conditions and in such amounts as the Management Committee in its
sole discretion deems fair and reasonable to the Company. In accordance with Section 4.1(f)(xvii), the Company has reserved
Membership Interests for issuance to New Investors in connection with their purchase of Membership Interests in a New Investment
Round in an amount that, when aggregated with all other Membership Interests outstanding, would entitle such New Investors to
own not more than one-third (1/3) of the total amount of Membership Interests outstanding immediately subsequent to such issuance.
Such issuance shall dilute the Membership Interests of the existing Members, immediately prior to the consummation of the New
Investment Round, in proportion to their respective Membership Interests.

 

(b)          Anti-dilution
of BioLife. Upon the consummation of a New Investor Round, BioLife shall have the right, but not the obligation, to
make additional Capital Contributions, or to undertake in writing to the Company to make such additional Capital Contributions
thereafter and to acquire Membership Interests in accordance with any such additional Capital Contribution, in an amount (computed
at the same price per Membership Interests at which the New Investor purchases its Membership Interests) that, when aggregated
with all other Membership Interests owned by BioLife, shall entitle BioLife to own not more than fifteen (15%) percent of the
total amount of Membership Interests outstanding immediately subsequent to such consummation. The Management Committee is expressly
authorized to issue any such Membership Interests to BioLife in accordance with Section 4.1(f)(xvii). In the event BioLife
gives a written undertaking as set forth above, such undertaking shall be acceptable in form and substance to the Management Committee
in its sole discretion.

 

3.8         Members’
Limited Liability. The liability of each Member, as such, shall be limited to the amount of such Member’s Capital Contributions
in accordance with the provisions hereof. None of the Members shall have any further personal liability to contribute money to
or in respect of the liabilities or the obligations of the Company, nor shall any Member be personally liable for any other obligations
of the Company solely by reason of being a member of the Company. Each Member understands, however, that, to the extent required
by Section 18-607 of the Act, if such Member knowingly receives a Distribution from the Company in violation of subdivision (a)
of Section 18-607 of the Act, such Member may be liable to the Company for the amount of such Distribution; but nothing herein
is intended to or shall expand the rights, if any, that a creditor may have under law apart from this Agreement.

 

    	 	11	 

     

    

 

3.9         Negative
Capital Account. A “Negative Capital Account” resulting from any Distribution in accordance with the provisions
of this Agreement, or from losses, is hereby recognized as a possibility under this Agreement, and such Negative Capital Account
shall not affect a Member’s participation in the Profits and Losses of the Company. In no event shall a Member be required
at any time to restore a Negative Capital Account or shall such Negative Capital Account be in any way considered a liability
of such Member or an asset of the Company.

 

3.10       No
Fiduciary Relationship Among Members and Management Committee. Except as otherwise expressly and specifically provided in
this Agreement or as required under the Act:

 

(a)          the
Members and Managers shall have no fiduciary relationship to the other Members and Managers solely by reason of their status as
Members and Managers (as the case may be);

 

(b)          no
Member or Manager shall have any authority to bind or act for, or assume any obligations or responsibility on behalf of, any other
Member or Manager (as the case may be);

 

(c)          neither
the Company nor any Member nor any Manager shall, by virtue of executing this Agreement, be responsible or liable for any indebtedness
or obligation of the other Members or Managers (as the case may be); and

 

(d)          the
rights of each of the Members and Managers and the Company to sue for matters and claims arising out of or pertaining to this
Agreement shall not be dependent upon the dissolution, winding up or termination of the Company.

 

3.11       Outside
Interests. A Member or an Affiliate of a Member may, directly or indirectly, own, manage, operate, control, be employed by,
participate in, be financially interested in or represent, or render any advice or services to any other business, independently
or with others. Neither the Company nor the other Members shall have, nor have the right to acquire, any right, by virtue of this
Agreement, in and to any such permitted venture or to the income or profits derived therefrom.

 

ARTICLE IV

RIGHTS, DUTIES AND POWERS OF

MANAGEMENT COMMITTEE AND MEMBERS

 

4.1         Rights,
Powers and Duties of Management Committee.

 

(a)          The
business and affairs of the Company shall be managed exclusively by or under the direction of a Management Committee consisting
of three (3) Managers who initially shall be the Initial Managers. It is acknowledged that Dana Barnard and Bruce McCormick have
been designed as Managers by Savsu and Michael Rice has been designated as a Manager by BioLife. Upon the consummation of a New
Investment Round, the composition of the Management Committee shall be increased to four (4) Managers and such additional Manager
shall be designated by the New Investor. The Management Committee shall possess and enjoy all of the management rights and powers
provided in the Act and shall conduct and manage the business of the Company in accordance with the provisions of the Act and
the terms of this Agreement. Except as otherwise provided herein, the Managers shall devote such time and attention to the management
of the Company as they deem necessary, but shall not be required to devote any specified amount of time or attention to the affairs
of the Company. Except as otherwise provided in this Agreement, no Manager shall receive any compensation for any management services
provided by him or her, but shall be reimbursed for reasonable out of pocket expenses incurred on behalf of the Company.

 

    	 	12	 

     

    

 

(b)          No
Member, solely by reason of being a Member, shall be an authorized agent of the Company.

 

(c)          Each
Manager shall have one vote. Except as expressly stated otherwise herein, all actions by the Management Committee will require
the approval of at least a majority of the Managers (by number).

 

(d)          Following
a valid vote taken by the Management Committee in respect of any action on behalf of the Company, the President shall be the agent
of the Company for the purpose of effecting such action, and the act of the President, if any, or any other individual authorized
by the Management Committee, including the execution in the name of the Company of any agreement, document or instrument, for
apparently carrying on such action in the usual way of the business of the Company, shall bind the Company.

 

(e)          Each
Manager shall have the right to authorize, by written notice to the other Managers, his or her Representative as his or her delegate
to attend meetings of the Management Committee on his or her behalf and exercise all of such Manager’s authority for all
purposes until the appointment is revoked.

 

(f)          Without
limiting the forgoing general powers set forth in this Section 4.1, the Management Committee is hereby authorized and empowered
on behalf and in the name of the Company to do any and all of the following, subject to the provisions of Section 4.3:

 

(i)          appoint,
delegate authority to, remove and terminate such employees, officers, agents and consultants, including without limitation, attorneys,
accountants and other professional advisors, as the Management Committee considers appropriate;

 

(ii)         sell,
exchange, lease, mortgage, pledge, or otherwise transfer all or any portion of the assets of the Company;

 

(iii)        make
any loan by the Company to, or guarantee the indebtedness of, any other Person;

 

    	 	13	 

     

    

 

(iv)        create
any new class of Membership Interests not initially named or specified herein;

 

(v)         borrow
money on behalf of the Company on such terms and conditions as the Management Committee shall determine;

 

(vi)        make
all tax elections on behalf of the Company;

 

(vii)       invest
the assets of the Company in interests in any issuer, wherever such issuer may be located, organized or operated, whether within
or without the United States of America, without limitation as to marketability of the securities or other interests reflecting
such investments;

 

(viii)      employ
one or more custodians of the assets of the Company;

 

(ix)         vote,
give assent and otherwise exercise all rights, powers, privileges and other incidents of ownership or possession with respect
to assets of the Company; and execute and deliver proxies or powers of attorney to such person or persons as the Management Committee
shall deem proper, granting to such person or persons such power and discretion with relation to the Company’s assets as
the Management Committee shall deem proper;

 

(x)          institute,
prosecute, defend, settle, compromise or otherwise adjust all claims, including but not limited to claims for taxes, and litigation
arising out of the conduct or the affairs of the Company or in the enforcement of obligations due it, including all rights of
appeal;

 

(xi)         employ
or consult with such agents or independent contractors as the Management Committee may deem necessary or advisable, including
without limitation, brokers, auditors, counsel, investment advisers, managers or specialists in any field or endeavor whatsoever,
including such persons or companies as may be Members or Affiliates of any Members;

 

(xii)        pay
or cause to be paid all expenses, fees, charges, taxes and liabilities incurred or arising in connection with the conduct of the
affairs of the Company;

 

(xiii)       enter
into joint ventures, general or limited partnerships and any other combinations or associations, or enter into any transaction
resulting in or constituting a Change in Control of the Company;

 

(xiv)      purchase
and pay for such insurance as the Management Committee shall deem necessary, desirable or appropriate for the conduct of the Business;

 

(xv)       make,
issue, accept, endorse and execute promissory notes, drafts, bills of exchange and other instruments and evidences of indebtedness,
and secure the payment thereof by mortgage, pledge, or assignment of or security interest in all or any part of the assets then
owned or thereafter acquired by the Company;

 

    	 	14	 

     

    

 

(xvi)      enter,
make and perform such other contracts, agreements and other undertakings as may be necessary, desirable or advisable or incidental
to the carrying out of any of the foregoing powers, objects or purposes, including contracts, agreements and undertakings with
Affiliates of the Members;

 

(xvii)     Issue
Membership Interests to New Investors and BioLife in accordance with Section 3.7(a) and Section 3.7(b); and

 

(xviii)    execute
all other instruments of any kind or character and take all action of any kind or character which the Management Committee may
in its sole discretion determine to be necessary or appropriate in connection with the Business.

 

4.2         Appointment
and Removal of Managers. So long as a Manager is willing and able to serve in such capacity, he or she may be removed as a
Manager only by the vote of the Member who originally designated that Manger (the “Designating Member”). If,
at any time, a Manager is unwilling or unable to serve as a Manager or upon the death or incapacity of a Manager, the resulting
vacancy on the Management Committee shall be filled by the vote of the Designating Member. Such replacement Manager shall be subject
to the provisions of this Agreement as if he or she had been appointed upon its execution.

 

4.3         Limitation
of Powers.  The Management Committee may not, without the approval of Members holding a Supermajority of the Membership
Interests, take any of the following actions:

 

(a)          Sell,
exchange, or otherwise dispose of or agree to sell or exchange or otherwise dispose of all or substantially all of the property
or assets of the Company and/or the Membership Interests of the Company for property, cash, or on terms (or any combination thereof),
except in a liquidating sale upon dissolution of the Company;

 

(b)          Except
to the extent specifically provided in Section 3.7(a) and Section 3.7(b), issue additional Membership Interests
to any Person, or grant options pursuant to a plan or otherwise to employees of the Company to purchase existing Membership Interests
or other newly-created classes of Membership Interests;

 

(c)          Acquire
any business or Person for an aggregate purchase price of more than $1,000,000;

 

(d)          Merge
or consolidate with any other Person, if the Company is not the surviving entity;

 

(e)          Recapitalize,
split up and/or combine the existing Membership Interests of the Company (other than in connection with the consummation of a
New Investment Round;

 

    	 	15	 

     

    

 

(f)          Enter
into any transaction, the effect of which would be to cause a Change in Control of the Company;

 

(g)         Cause
the Company to issue securities in an initial public offering thereof;

 

(h)         Make
a material change in the nature of the Business of the Company;

 

(i)          Repay
any indebtedness owed by the Company in excess of $1,000,000 prior to the maturity thereof;

 

(j)          Take
any voluntary action which constitutes a Bankruptcy Event;

 

(k)         Dissolve
the Company in accordance with Article IX;

 

(l)          Enter
into any transaction with any Affiliate of a Manager other than in accordance with Section 4.11;

 

(m)        Do
any act in contravention of this Agreement or the Certificate;

 

(n)         Do
any act that would make it impossible to carry on the business of the Company, except in a liquidating sale upon dissolution of
the Company; or

 

(o)          Knowingly
take any action that would subject any Member to personal liability in any jurisdiction.

 

4.4         Indemnification
and Exculpation of Members and Managers.

 

(a)          Each
Member and each Manager (including any testator or intestate of any such Member or Manager) and, to the extent any such Member
or Manager is not a natural person, each Member’s or Manager’ members, Managers, directors, officers, employees or
agents acting on its behalf (and the Affiliates of each of them) (“Indemnified Parties”) shall be held harmless
and indemnified by the Company from any liability, loss, cost or expense (including, without limitation, judgment, fines, amounts
paid in settlement, attorneys’ fees and expenses actually and necessarily incurred) arising out of any action or proceeding
arising out of any act taken in the capacity of a Member or Manager (or a member, manager, director, officer, employee or agent
thereof) or any failure to take action in such capacity in connection with activities of the Company; provided, however,
that no indemnification may be made to or on behalf of any Indemnified Party if a judgment or other final adjudication adverse
to the Indemnified Party establishes (i) that the acts in question were committed in bad faith or were the result of active and
deliberate dishonesty and were material to the cause of action so adjudicated, or (ii) that the Indemnified Party or a principal
of the Indemnified Party personally gained in fact a financial profit or other advantage to which the Indemnified Party or any
such principal was not legally entitled. The Company shall advance to each Indemnified Party any expenses incurred by the Indemnified
Party in the defense of any action or proceeding arising out of any act taken in the capacity of a Member or Manager (or a member,
manager, director, officer, employee or agent thereof) or any failure to take action in such capacity in connection with activities
of the Company upon the written undertaking of the Indemnified Party to reimburse the Company therefor in the event that such
Indemnified Party is ultimately found not to be entitled to indemnification as a result of the proviso set forth above.

 

    	 	16	 

     

    

 

(b)          A
Manager (including any testator or intestate of such Manager) and, to the extent a Manager is not a natural person, each of such
Manager’s, members, Managers, directors, officers, agents or employees acting on its behalf (“Exculpated Parties”)
shall not be liable to the Company or any Member for any damages suffered by the Company or any Member as a result of any breach
of duty by any Exculpated Party in the capacity of a Manager, except to the extent that a judgment or other final adjudication
adverse to the Exculpated Party, or a principal of such Exculpated Party, establishes that the acts or omissions of the Exculpated
Party, or a principal of such Exculpated Party, were in bad faith or involved intentional misconduct or a knowing violation of
law or that the Exculpated Party, or a principal of such Exculpated Party, personally gained in fact a financial profit or other
advantage to which the Exculpated Party, or a principal of such Exculpated Party, was not legally entitled or that with respect
to a Distribution the subject of subsection (a) of Section18-607 of the Act, the acts of the Exculpated Party, or a principal
of such Exculpated Party, were not performed in accordance with Section 18-607 of the Act.

 

4.5         Books,
Records and Reports.

 

(a)          At
all times during the continuance of the Company, the Management Committee shall keep or cause to be kept full and true books of
account in accordance with Section 11.1. All of the books of account, together with (i) a current list of the full name
set forth in alphabetical order and last known mailing address of each Member, together with the Capital Contribution and the
share in Profits and Losses of each Member or information from which such share can be readily derived; (ii) a copy of the Certificate
of Formation and all amendments thereto, or restatement thereof, together with executed copies of any powers of attorney pursuant
to which any certificate of amendment has been executed; (iii) a copy of this Agreement, any amendments thereto; and (iv) a copy
of the Company’s Federal, state and local income tax or information returns and reports, if any, for the three most recent
fiscal years, shall at all times be maintained at the principal office of the Company, or at such other office (in the State of
New York) as the Management Committee may designate by written notice to all Members. Any Member or its, his or her duly authorized
representative may inspect and copy at its, his or her own expense for any purpose related to the Member’s Membership Interest
the records referred to in this Section 4.5, at any time during regular business hours upon reasonable prior notice to
the Company.

 

(b)          The
Management Committee shall cause to be prepared all federal, state and local tax returns required to be filed. Each Member shall
notify the other Members upon receipt of any notice of tax examination of the Company by federal, state or local authorities.
Notwithstanding anything herein to the contrary, Savsu shall have the right to review and comment on all federal, state and local
tax returns and filings, and all schedules and forms, of the Company, before they are filed with federal, state or local taxing
authorities.

 

(c)          The
Company shall have prepared annual reviewed financial statements prepared in accordance with GAAP by an outside certified public
accountant as may be engaged by the Management Committee (each, an “Annual Financial Statement”).

 

    	 	17	 

     

    

 

(d)          The
Company shall deliver to each Member the following:

 

(i)          At
the earliest practicable date following the end of each quarter of the Company’s Fiscal Year, as determined by the Management
Committee, a balance sheet, income statement and statement of cash flows of the Company and a statement of each Member’s
Capital Account (all of which may be unaudited) as of the end of such fiscal quarter;

 

(ii)         At
the earliest practicable date following the end of each Fiscal Year, as determined by the Management Committee, a balance sheet,
income statement and statement of cash flows of the Company and a statement of each Member’s Capital Account (all of which
shall be audited by an independent certified public accountant engaged by the Company) as of the end of such Fiscal Year;

 

(iii)        At
the earliest practicable date following the end of each Fiscal Year, information necessary for the preparation by each Member
of its, his or her Federal Income Tax Return as to the Company’s income, gain, and loss or deductions, if any, including
a copy of the Federal Partnership Return to be filed by the Company with the Internal Revenue Service, showing the income, gain,
credit and loss and deductions, if any, of the Company and the allocations thereof to each Member for said Fiscal Year; and

 

(iv)        At
the earliest practicable date following the end of each Fiscal Year, as determined by the Management Committee, a copy of the
Company’s annual capital and operating budgets.

 

4.6         Tax
Matters.

 

(a)          The
Management Committee shall designate a tax matters partner for purposes of Federal and state income tax matters. The tax matters
partner shall cause the preparation and timely filing of all tax returns required to be filed by the Company pursuant to the Code
and all other tax returns deemed necessary and required in each jurisdiction in which the Company does business.

 

(b)          The
expenses of professional representation during any tax audit controversy or dispute involving the Company shall be a Company expense
payable out of Company funds.

 

(c)          The
tax matter partner may, in its, his or her sole discretion, settle or dispose of any tax controversy or dispute affecting the
Company or any of the tax positions taken by the Company.

 

4.7         Status
of Members.

 

(a)          No
Member shall be subject to calls or assessments for Capital Contributions in excess of such Member’s Capital Contributions
as of the Effective Date.

 

    	 	18	 

     

    

 

(b)          No
Member shall have contractual appraisal rights with respect to such Member’s Membership Interest in the Company in connection
with any amendment of this Agreement, any merger or consolidation in which the Company is a constituent party to such merger or
consolidation, any conversion of the Company to another business form, any transfer to or domestication or continuance in any
jurisdiction by the Company, or the sale of all or substantially all of the Company’s assets (each of which actions shall
require the unanimous vote of the Management Committee).

 

4.8         Meetings
of Members and the Management Committee. Meetings of Members and/or the Management Committee shall be called by any Manager,
in his/her discretion or in the case of a meeting of the Members upon the request of Members holding [fifteen (15%)] percent or
more of the Membership Interests, at the office of the Company or such other place within the State of New York as the Management
Committee shall determine. Each Member and Manager shall receive notice of such meeting from the Management Committee or Members,
as the case may be, shall have the right to attend each Meeting of the Company for the transaction of business of the Company.
Notice stating the time and place of the Meeting and describing the matters to be discussed at the Meeting shall be provided to
each Member and Manager, as the case may be, not less than ten (10) days and not more than ninety (90) days prior to the Meeting.
Whether or not a quorum is present, a meeting of Members may be adjourned by a vote of at least a majority of the Membership Interests
that are present at the meeting (in person or by proxy). No notice need be given of an adjourned meeting, provided that
the date, time and place to which a meeting is adjourned are announced at the meeting at which the adjournment is taken. At any
meeting or adjourned meeting of the Members or Management Committee, as the case may be, the only business that may be transacted
is limited to the matters specified in the notice of meeting. Each meeting shall be conducted by the Management Committee. A valid
vote for the taking of an action on behalf of the Company by the Members shall mean the affirmative vote of Members who are holders
of at least a majority of the Membership Interests who are present in person or by proxy at a duly called meeting at which a quorum
is present unless otherwise stated in this Agreement. A quorum for a meeting of Members shall consist of the Members (as of the
date of the meeting, or, if a record date has been specified for the meeting, as of the record date) are holders of at least a
majority of the Membership Interests.

 

4.9         Action
by Members or Management Committee Without a Meeting.

 

(a)          Whenever
the Members or Management Committee are required or permitted to take any action by vote, or any consent of the Members or Management
Committee is required hereunder, such action may be taken, or such consent given, without a meeting and without a vote, if a consent
or consents in writing, setting forth the action so taken shall be signed by: (i) for Members, the Members who hold Membership
Interest representing not less than the minimum number of Membership Interests, or (ii) for the Management Committee, by affirmative
vote of a majority of the Managers, by number, in each case, that would be necessary to authorize or take such action at a meeting
at which all of the Members or Management Committee, as the case may be, entitled to vote thereon were present and voted, or;
and provided further that each Member and Manager, as the case may be, shall receive notice of such consent from the Management
Committee prior to the execution of such consent. All such consents shall be delivered to the principal office of the Company,
or a Manager, employee or agent of the Company having custody of the records of the Company. Delivery made to the principal office
of the Company or Manager, employee or agent shall be by hand or by certified or registered mail, return receipt requested.

 

    	 	19	 

     

    

 

(b)          Prompt
notice of the taking of the action without a meeting by less than unanimous written consent of all Members shall be given to those
Members who have not consented in writing, but would have been entitled to vote thereon had such action been taken at a meeting.

 

4.10       Confidentiality.

 

(a)          Each
Member and Manager agrees not to disclose or permit the disclosure of and shall keep confidential all information furnished to
the Members and their Affiliates by or on behalf of the Company, including without limitation all information relating to the
Company’s products, customers, suppliers, business, financial condition or operations (“Confidential Information”)
provided, that disclosure may be made (i) to any person who is a Member, or a member, manager, officer, director or employee
of such Member or counsel to, accountants of, investment bankers for or consultants to, such Member or the Company solely for
its, his or her use with respect to and in connection with such Member’s Membership Interest and on a need-to-know basis,
and who shall be advised of and agree to preserve the confidential nature of such information, (ii) with the prior consent of
the Management Committee, or (iii) pursuant to a subpoena or order issued by a court, arbitrator or governmental body, agency
or official or in order to comply with any law, rule or regulation.

 

(b)          In
the event that a Member, or any member, manager, officer, director or employee of such Member or any of its counsel, accountants,
investment bankers or consultants, shall receive a request to disclose any of the terms of this Agreement or any other Confidential
Information under a subpoena or order, such Member shall promptly notify and consult with the Management Committee on the advisability
of taking steps to resist or narrow such request and, if disclosure is required or deemed advisable, cooperate with the Management
Committee in any attempt they may make to obtain an order or other assurance that confidential treatment will be accorded those
terms of this Agreement or such other Confidential Information that are required to be disclosed.

 

(c)          Notwithstanding
the foregoing, information shall not constitute Confidential Information, to the extent it (i) is or becomes generally available
to the public other than as a result of a disclosure by a Member or its Affiliates in contravention of this Agreement, (ii) was
already in the possession of the Member or its Affiliates on a non-confidential basis prior to its disclosure to the Member or
its Affiliates by or on behalf of the Company; or (iii) is or becomes available to the Member or its Affiliates on a non-confidential
basis from a source other than the Company or another Member of the Company or such other Member’s Affiliates.

 

(d)          In
the event of a breach or threatened breach by any Member of the covenants contained in this Section 4.10, the Management
Committee, acting on behalf of the Company, shall be entitled (i) to obtain an injunction or other equitable relief to restrain
or enjoin such breach or threatened breach, without any requirement to post a bond, and (ii) to recover the Company’s legal
fees incurred as a result of the breach or threatened breach.

 

    	 	20	 

     

    

 

4.11       Dealing
with Members. The fact that a Member, an Affiliate of a Member, or any member, manager, officer, director, employee, partner,
consultant or agent of a Member or an Affiliate of a Member, is directly or indirectly interested in or connected with any Person
employed by the Company to render or perform a service, or from or to whom the Company may buy or sell any property or have other
business dealings, shall not prohibit the Company from employing such Person or from dealing with him or her on customary terms,
and at rates of compensation, no less favorable to the Company than it would obtain in an arms’ length transaction between
or among unrelated parties, as determined in the sole discretion of the Management Committee, and neither the Company nor any
of the Members shall have any rights in or to any income or profits derived therefrom by such interested Person.

 

(a)          Notwithstanding
any duty otherwise existing or anything to the contrary law (whether common or statutory), in equity or otherwise, to the fullest
extent permitted by law (including Section 18-110 of the Act), the only duties of an Indemnitee to the Company or to any other
Indemnitee hereunder or under law (whether common or statutory), in equity or otherwise are limited solely to performing those
contractual duties explicitly set forth herein, in such manner and under such standards as expressly set forth herein, and the
Indemnitees shall have no additional or other duties (including fiduciary duties) to the Company or the other lndemnitees hereunder
or under law (whether common or statutory), in equity or otherwise, any such additional or other duties (including fiduciary duties)
being hereby eliminated; provided, however, that nothing in this Agreement shall be construed as eliminating the
implied contractual covenant of good faith and fair dealing.

 

(b)          To
the extent that, law (whether common or statutory) or in equity, an Indemnitee has duties (including fiduciary duties) and liabilities
relating to the Company, other Indemnitees, as the case may be, acting under this Agreement, shall, to the fullest extent permitted
by law, not be liable to the Company, to any other Indemnitee for its good faith reliance on the provisions of this Agreement.

 

(c)          The
provisions of this Agreement, to the extent that they restrict or eliminate the duties (including fiduciary duties) and liabilities
of an Indemnitee otherwise existing law (whether common or statutory) or in equity or otherwise, are agreed by the Members to
replace (or eliminate, as the case may be) such other duties (including fiduciary duties) and liabilities of the Indemnitees,
as the case may be, to the fullest extent permitted by law (including Section 18-1101 of the Act); provided, however,
that nothing in this Agreement shall be construed as eliminating the implied contractual covenant of good faith and fair dealing.

 

(d)          To
the fullest extent permitted by applicable law, and notwithstanding any other provision of this Agreement or in any agreement
contemplated herein, or law (whether common or statutory) or equity or otherwise, whenever in this Agreement a Person is permitted
or required to make a decision in its “sole discretion” or “discretion” or under a grant of similar authority
or latitude, such Person shall be entitled to consider such interests and factors as it desires, including its own interests,
and shall have no duty or obligation to give any consideration to any interest of or factors affecting the Company or any other
Person, provided that nothing in this Section 4.11 shall be construed as eliminating the implied contractual covenant
of good faith and fair dealing.

 

    	 	21	 

     

    

 

(e)          The
foregoing provisions of this Section 4.11 shall (a) survive any termination of this Agreement and (b) be contract rights,
and no amendment, modification, supplement, restatement or repeal of this Section 4.11 shall have the effect of limiting
or denying any such rights with respect to Liabilities prior to any such amendment, modification, supplementation or repeal.

 

4.12       Royalties.
The Company and BioLife have entered into a Services Agreement, dated the date hereof, relating to the performance by BioLife
of services for the Company, on the terms and conditions set forth in the Services Agreement. The Company shall pay Royalties
to BioLife as and when provided in the Services Agreement.

 

ARTICLE V

OFFICERS

 

5.1         Officers.
The Management Committee shall, at their sole discretion, appoint and designate a President and such other persons as they deem
fit to serve as officers (each, an “Officer”) of the Company, with such duties and obligations as may be delegated
to such persons by the vote of a majority in number of the Management Committee, in their sole discretion, and subject to, at
all times, the Management Committee’s control and supervision. Initially, the President shall be Bruce McCormick. Subject
to the direction and oversight of the Management Committee, the President shall be responsible for the day-to-day operation and
management of the business and affairs of the Company. The Management Committee shall have the power to remove or replace any
Officer and to appoint new and/or additional Officers.

 

5.2         Indemnification
and Exculpation of Officers

 

(a)          The
Company shall indemnify, defend and hold each Officer harmless from any liability, loss, cost or expense (including, without limitation,
judgment, fines, amounts paid in settlement, attorneys’ fees and expenses actually and necessarily incurred) arising out
of any action or proceeding arising out of any act taken in the capacity of an Officer or any failure to take action in such capacity
in connection with activities of the Company; provided, however, that no indemnification may be made to or on behalf
of any Officer if a judgment or other final adjudication adverse to the Officer establishes (i) that the acts in question were
committed in bad faith or were the result of active and deliberate dishonesty and were material to the cause of action so adjudicated,
or (ii) that the Officer personally gained in fact a financial profit or other advantage to which the Officer was not legally
entitled. The Company shall advance to each Officer any expenses incurred by the Officer in the defense of any action or proceeding
arising out of any act taken in the capacity of an Officer or any failure to take action in such capacity in connection with activities
of the Company upon the written undertaking of the Officer to reimburse the Company therefor in the event that such Officer is
ultimately found not to be entitled to indemnification as a result of the proviso set forth above.

 

(b)          An
Officer shall not be liable to the Company, any Manager and/or any Member for any damages suffered by the Company or any Member
or Manager as a result of any breach of duty by any Officer in the capacity of an Officer, except to the extent that a judgment
or other final adjudication adverse to the Officer establishes that the acts or omissions of the Officer were in bad faith or
involved intentional misconduct or a knowing violation of law or that the Officer personally gained in fact a financial profit
or other advantage to which the Officer was not legally entitled or that with respect to a Distribution the subject of subsection
(a) of Section 18-607 of the Act, the acts of the Officer were not performed in accordance with Section 18-607 of the Act.

 

    	 	22	 

     

    

 

ARTICLE VI

INTELLECTUAL PROPERTY

 

6.1         Initial
Assignments of Intellectual Property.

 

(a)          Assignment
by Savsu. The parties confirm that Savsu has assigned to the Company all of its right, title and interest to and to the Savsu
Patents and all intellectual property rights contained therein and appurtenant thereto.

 

(b)          Assignment
by BioLife. The parties confirm that BioLife has assigned to the Company all of its right, title and interest to and to the
BioLife Copyrights and all intellectual property rights contained therein and appurtenant thereto.

 

(c)          Disclosure
of Future Inventions. Each Member shall promptly communicate and disclose to the Company Inventions all original works of
authorship, software applications, computer code, inventions, ideas, discoveries, improvements, modifications, writings, artistic
or creative material, and other intellectual property in any form whatsoever (whether or not patented and/or copyrighted), conceived,
developed, or made by the Member and/or its employees and/or agents whether solely or jointly with others and whether or not patentable
or copyrightable, (a) which relate to the Business, or (b) which result from or are suggested by any work performed by the Member
in connection with the Business.

 

(d)          Property.
All materials, records, and documents (in any form) made by each Member or coming into his possession concerning the Business
of the Company will be the sole property of the Company. Each Member shall promptly deliver the original and all copies (whether
physical or electronic) thereto to the Company. Each Member agrees to render to the Company reports of the activities undertaken
by the Member or conducted under the Member’s direction pursuant to this provision, as the Company may request from time
to time.

 

(e)          Assignment.
Each Member hereby assigns to the Company all of his rights in the Inventions conceived, developed, or made by the Member in connection
with and/or relating to the Business of the Company whether solely or jointly with others, while he is a Member. Each Member agrees
to assist and cooperate with the Company at the Company’s sole expense, in filing patent and/or copyright applications on,
and obtaining for the Company’s benefit, patents and/or copyright applications, and all patents and/or copyrights which
may issue thereon. The Inventions are, shall be, and shall remain the sole and exclusive property of the Company.

 

(f)          Original
Works. Any copyrightable work (including, but not limited to, software code and applications), whether published or unpublished,
created by a Member in connection with or during the performance of his duties or services as a Member, employee, consultant or
in any other capacity for the Company shall be considered a work made for hire to the fullest extent permitted by law, and all
right, title and interest therein, including the worldwide copyrights, shall be the sole and exclusive property of the Company
as the employer and party specially commissioning such work. In the event that any such copyrightable work or portion thereof
shall not be legally qualified as a work made for hire, or shall subsequently be so held, each Member agrees to properly convey
to the Company the entire right, title and interest in and to such work or portion thereof, including but not limited to the worldwide
copyrights, extensions of such copyrights, and renewal copyrights therein, and further including all rights to reproduce the copyrighted
work, to prepare derivative works based on the copyrighted work, to distribute copies of the copyrighted work, to display the
copyrighted work, and to register the claim of copyright therein and to execute any and all documents with respect hereto.

 

    	 	23	 

     

    

 

ARTICLE VII

TRANSFERS OF MEMBERSHIP INTERESTS

 

7.1         Restriction
on Transfer. Except as expressly permitted by this Article VII, a Member may not Transfer all or any portion of a Membership
Interest, nor enter into any agreement as a result of which any other person shall become interested in the Company, including
any purported assignment of the economic rights only, without the prior written consent of the Management Committee in its sole
discretion. For the purposes of this Article VII, a Transfer shall include and encompass (i) a voluntary action of a Member,
(ii) a Transfer of an existing equity interest in a Member or the issuance of a new equity interest in a Member or some combination
of both the effect of which is to change the Person or Persons who have management control of the Member at the time of the execution
of this Agreement, or (iii) any involuntary Transfer, as described in Section 7.2, which may occur with respect to such
equity interest.

 

7.2         Involuntary
Transfer. In the event of the death, incapacity, Bankruptcy Event or other event which results in an involuntary Transfer
of a Member’s Membership Interest (including, without limitation, a transfer by way of attachment, levy, foreclosure, sheriffs’
or other judicial sale, or pursuant to a divorce decree), then such Membership Interest shall be deemed to have been offered,
in full, for sale (a “Deemed Sale”) to the other Members immediately prior to such event pursuant to the provisions
of this Article VII. Each Member has the right to purchase, in full, its, his or her pro rata share of the Membership Interest
offered in a Deemed Sale for a purchase price, in the case of an involuntary Transfer equal to (a) the FMV, multiplied by (b)
such Membership Interest, expressed as a percentage. The closing of a Deemed Sale shall occur no later than thirty (30) days after
the date of the event resulting in an involuntary Transfer of a Member’s Membership Interest. The Member or his or her estate
or legal representatives, if any, shall be entitled to payments in respect of the FMV of such Membership Interest in equal monthly
installments over a thirty six (36) month period, bearing interest at the short-term monthly Applicable Federal Rate as of the
date of closing.

 

7.3         Drag
Along Rights. Subject to Section 7.1, if one or more Members (the “Selling Member(s)”) collectively
seek to Transfer not less than a Supermajority of the Membership Interests (the “Supermajority Interest”) to
a purchaser who is not a Member or an Affiliate of a Member (a “Majority Purchaser”), the Selling Member(s),
after obtaining the prior written consent of the Management Committee, may, by giving twenty (20) days written notice to the remaining
Members (the “Non-Selling Member(s)”), demand that the Non-Selling Member(s) Transfer a pro rata portion of
the Membership Interests which they own to the Majority Purchaser upon Transfer of the Interest to such Majority Purchaser (the
“Drag-Along Option”). If the Selling Member(s) exercises its Drag-Along Option, the Non-Selling Member(s) shall
be required to Transfer their Membership Interest to the Majority Purchaser at the same price and on the same terms and conditions
under which the Selling Member(s) shall Transfer the Supermajority Interest to the Majority Purchaser; provided, however, that
no Member shall be required to assume any liability or obligation in connection with such sale without its written consent except
with respect to customary representations as to such Member’s title to the Membership Interest being transferred and the
due authority and authorization, if necessary, to Transfer such Membership Interest. Each of the Non-Selling Member(s) shall,
at the request of the Selling Member(s), become a party to the purchase agreement or other agreement for the sale of the Supermajority
Interest, and, shall, among other things, join in any other representations and warranties made therein.

 

    	 	24	 

     

    

 

7.4         Tag
Along Rights. Subject to Section 7.1, if any Member receives a written offer (the “Offer”) from
a Person who is not a Member or an Affiliate of a Member, for the Transfer of any or all of his or her Membership Interests without
exercising the Drag-Along Option, if applicable, such Member, after obtaining the prior written consent of the Management Committee,
shall promptly forward a copy of such Offer to the other Member(s), together with a notice from such Member that Member desires
to sell such Membership Interests. Such notice shall specify the number of Membership Interests which such Member desires to sell,
the percentage that such Membership Interests represent of the total percentage of Membership Interests owned by the Selling Member,
the identity of the proposed purchaser of the Membership Interests, and all of the material terms of the Offer, the Non-Selling
Member(s) may, by [ten (10)] days written notice to such Member, demand that the Selling Member(s) include in such Transfer, such
Non-Selling Member(s) entire Membership Interest, if Transferring its entire Membership Interest, or a pro rata portion of the
Non-Selling Member(s)’ Membership Interest in the event the Selling Members are Transferring less than all of its Membership
Interest to the Purchaser (the “Tag-Along Option”). If the Non-Selling Member(s) exercise their Tag-Along Option,
the Non-Selling Member(s) shall be required to so transfer their Membership Interests to the purchaser at the same price and on
the same terms and conditions under which such selling Member(s) shall transfer the Membership Interest to the purchaser; provided,
however, that no Member shall be required to assume any liability or obligation in connection with such sale without its consent
except with respect to customary representations as to such Member’s title to the Membership Interest being transferred
and the due authority and authorization, if necessary, to transfer such Member’s Membership Interest. Each of the Non-Selling
Member(s) that exercise the Tag-Along Option shall, at the request of such Selling Member, become a party to the purchase or other
agreement for the sale of the Membership Interests, and shall, among other things, join in any other representations and warranties
made therein. No Transfers to the purchaser shall be made pursuant to this Section 7.4 unless the purchaser accepts the
Transfer of and agrees to purchase all of such Selling Member(s)’ and Non-Selling Member(s)’ Membership Interest being
Transferred pursuant to this Section 7.4.

 

7.5         Relationship
of Assignees and Substituted Members.

 

(a)          No
Assignee shall have the right to participate in the Company, inspect the books of account of the Company or exercise any other
rights of a Member until admitted as a Substituted Member. An Assignee shall be entitled to share in the Profits and Losses of
the Company and receive Distributions from the Company; provided, however, that no assignment shall be binding on
the Company until written notice thereof is received by the Company. An Assignee may become a Substituted Member only upon the
terms and conditions set forth in Section 7.5(b).

 

    	 	25	 

     

    

 

(b)          In
order to become a Substituted Member, an Assignee of a Membership Interest must first obtain the prior unanimous consent of the
Management Committee. The admission of a Substituted Member shall be conditioned upon the Substituted Member’s written acceptance
and adoption of all of the terms and provisions of this Agreement. Any Substituted Member shall remain liable for the obligations
of the assignor of its Membership Interest to make the Capital Contributions required of such assignor pursuant to this Agreement.

 

ARTICLE VIII

PROFITS, LOSSES AND DISTRIBUTIONS

 

8.1         Distributions
from Operations. Provided the Distribution is not in connection with a Liquidity Event or the complete liquidation of the
Company or the complete liquidation of a Member’s Membership Interest in the Company, all Distributions of Available Cash
from Operations shall be made at such times and in such amounts as the Management Committee shall in its sole discretion determine;
provided, however, that, notwithstanding anything to the contrary contained in this Agreement, if at the end of
any annual fiscal period in which the Company’s gross income for such period exceeds its gross costs and expenses for the
same period, then the Management Committee shall make aggregate distributions to the Members in such amounts and at such times
as the Management Committee in its sole discretion shall determine (but in no event less frequently than once each fiscal year,
on or before the sixtieth (60th) day following the end of each such fiscal year). Distributions of Cash from Operations,
when made, shall be Distributed in the following order of priority:

 

(a)          First,
all earned and unpaid Royalties shall be distributed to BioLife;

 

(b)          Second,
to the Preferred Members until the aggregate Distributions pursuant to this subsection (b) and Section 8.2(c) shall equal the
Preferred Capital;

 

(c)          Thereafter,
to the Members, pro rata in proportion to their respective Profits Percentages.

 

8.2         Distribution
of Proceeds from Liquidity Event or Liquidation. The net proceeds to the Company resulting from a Liquidity Event, including
the liquidation of any substantial portion of Company assets, shall be distributed and applied in the following order of priority:

 

(a)          First,
to the payment of the debts and liabilities of the Company (including all expenses of the Company incident to any such liquidation
of the Company or sale referred to immediately above), and to the setting up of any reserves which the Management Committee in
its sole discretion deems reasonably necessary for contingent, unmatured or unforeseen liabilities or obligations of the Company;

 

    	 	26	 

     

    

 

(b)          Second,
to the payment of loans made by Members to the Company, in accordance with the terms agreed among them and otherwise on a pro
rata basis, either by the payment thereof or the making of reasonable provision therefor;

 

(c)          Third,
to the Preferred Members until the aggregate Distributions pursuant to Section 8.1(b) and this subsection (c) shall equal their
Preferred Capital;

 

(d)          Thereafter,
after taking into account subsections (a), (b) and (c), the sum of the remaining balance of net proceeds resulting from the Liquidity
Event plus the Distributed Royalties (“Adjusted Net Proceeds”) (i) to Savsu in the amount of its Capital Percentage
multiplied by the Adjusted Net Proceeds (“Savsu Liquidation Amount”) and (ii) to Biolife in the amount of its
Capital Percentage multiplied by the Adjusted Net Proceeds, decreased by the Distributed Royalties (“Biolife Liquidation
Amount”).

 

In the event that
any Available Cash is held in reserve or escrow, when such amounts become distributable they shall be Distributed to the Members
pro rata in proportion to their respective Capital Percentages. In the event that the Liquidity Event is a sale of Membership
Interests, the contract of sale or purchase and sale agreement shall allocate the proceeds of such sale in a manner consistent
with the above provisions.

 

8.3         Allocations
of Profits and Losses. Net Income (or loss) of the Company and all items of which it consists shall be determined for all
purposes, separately and not cumulatively for each year, in accordance with the accounting methods used in preparing the Company’s
Federal Income Tax returns.

 

(a)          Profits
from Operations. Profits from Operations of the Company for each taxable year shall be allocated among the Members in the
following order of priority:

 

(i)          First,
to Biolife up to the amount of the Distribution of Royalties during such current taxable year as described in Section 8.1(a);
and

 

(ii)         Thereafter,
among the Members, pro rata in proportion to their relative Profits Percentages.

 

(b)          Losses
from Operations. Profits from Operations of the Company for each taxable year shall be allocated among the Members, pro rata
in proportion to their relative Profits Percentages in the following order of priority:

 

(i)          First,
after taking into account the Distributions pursuant to Sections 8.1(b) and 8.2(c), to the Preferred Members until each such Member’s
Preferred Basis shall have been reduced to zero;

 

(ii)         Thereafter,
among the Members pro rata in proportion to their relative Profits Percentages.

 

(c)          Profits
from a Liquidation Event. Profits from a Liquidation Event shall be allocated among the Members in the following order of
priority:

 

    	 	27	 

     

    

 

(i)          First,
to each Preferred Member in an amount equal to the difference between its Undistributed Preferred Capital and its Preferred Basis;

 

(ii)         Second,
to Savsu until its Adjusted Capital Account shall equal the Savsu Liquidation Amount (defined below); and

 

(iii)        Thereafter,
among the Members pro rata in proportion to their Capital Percentages.

 

(d)          Losses
from a Liquidation Event. Losses from a Liquidation Event shall be allocated among the Members in the following order of priority:

 

(i)          First,
to Biolife until its Adjusted Capital Account shall equal the Biolife Liquidation Amount (defined below); and

 

(ii)         Thereafter,
among the Members pro rata in proportion to their Capital Percentages.

 

(e)          If
the allocations set forth in subsections (c)(i) and (d)(i) above are insufficient to bring the Members’ Adjusted Capital
Accounts to the Savsu or Biolife Liquidation Amounts, as applicable, the Company shall make such special allocations or reallocate
Profits or Losses, as appropriate, in a manner consistent with Section 8.7(d), in order to meet the aforementioned targets.

 

8.4         Proration
of Allocations. If there is a transfer of a Membership Interest, a daily net allocation of the items or amounts allocated
pursuant to this Article VIII shall be computed by dividing the items or amounts for the period by the number of days in
the period. The result obtained shall be applied to the former Member and the present Member in proportion to the number of days
each of them was a Member in the Company for such fiscal year; provided, however, any item or amount arising from
the acquisition or disposition of Company assets shall be taken into account as of the date thereof.

 

8.5         Tax
Distributions. On or prior to April 1 of each Fiscal Year, the Management Committee shall use its best efforts to cause cash
Distributions to be made to the Members in an amount, when added to other cash Distributions received by the Members during the
previous Fiscal Year as a result of the Members’ ownership of their Membership Interests, enables each Member (and, if such
Member is a pass-through entity for federal income tax purposes, the members thereof) to pay timely federal, state and local taxes
attributable to items of Profits, Losses, deductions and credits from the Company. In making such distributions, the tax rate
paid by the Members will be determined to be the highest marginal Federal and State individual tax rates. For the avoidance of
doubt, Tax Distributions as set forth herein, shall be treated as advances in respect of such Member’s entitled to Distributions
under the provisions above.

 

8.6         Alternative
Minimum Tax. All Company items of income, gain, loss, deduction and credit shall be allocated for purposes of the alternative
minimum tax in a manner that satisfies the requirements of Section 1.704-1(b) of the Treasury Regulations and that results in
each Member being allocated during the term of the Company an amount of alternative minimum taxable income with respect to the
Company during such term equal to the amount of regular tax income allocated to such Member during such term.

 

    	 	28	 

     

    

 

8.7         Regulatory
and Special Allocations. Prior to making any allocations under Section 8.3 hereof, the following allocations
shall be effected in the order or priority in which they are listed:

 

(a)          Minimum
Gain Chargeback. This Agreement incorporates by reference the “Minimum Gain Chargeback Requirement” of
Section 1.704-2(f) of the Treasury Regulations and the “Partner Nonrecourse Debt Minimum Gain Chargeback” rules
of Section 1.704-2(I) of the Treasury Regulations.

 

(b)          Qualified
Income Offset.         If a Member unexpectedly receives any adjustment,
allocation or distribution described in Section 1.704-1(b)(2)(ii)(d)(4), (5) or (6) of the Treasury Regulations, items of Company
income and gain shall be specifically allocated to such Member in an amount and manner sufficient to eliminate, to the extent
required by the Treasury Regulations, the Adjusted Capital Account Deficit of such Member as quickly as possible, provided,
that an allocation pursuant to this Section 8.7 shall be made only if and to the extent that such Member would have an
Adjusted Capital Account Deficit after all other allocations provided for in Section 8.3 and this Section 8.7 hereof
tentatively have been made as if this Section 8.7(b) were not in this Agreement.

 

(c)          Special
Allocations. The following special allocations shall be made with respect to the taxable year of the Company for 2016 only:

 

(i)          100%
of the income from discharge of indebtedness, if any, resulting from the contribution of the Company’s indebtedness to Biolife
by Biolife to the capital of the Company in exchange for additional equity shall be specially allocated to Biolife; and

 

(ii)         100%
of Losses of the Company for 2016 shall be allocated first to Biolife until the percentage produced by dividing its Adjusted Capital
Account by the Members’ aggregate Adjusted Capital Accounts shall be equal to Biolife’s Capital Percentage.

 

(d)          Curative
Allocations. Subject to the provisions of Sections 8.7(a) and 8.7(b) above, if any allocation is made pursuant
to one or more of Sections 8.7(a) or 8.7(b), then items of income and gain (including gross income, if necessary)
and deduction and loss shall be allocated among the Members as soon as possible to restore the Capital Accounts to the balances
that would have existed if such allocations pursuant to Sections 8.7(a) and 8.7(b) had not occurred so as to preserve
the intended economic arrangement among the Members as otherwise expressed herein.

 

(e)          Limitation
on Losses. Notwithstanding anything else contained in this Agreement, Losses allocated to any Member pursuant to Section
8.3 of this Agreement shall not exceed the maximum amount of Losses that may be allocated without causing such Member to have
an Adjusted Capital Account Deficit at the end of the Fiscal Year for which the allocation is made.

 

    	 	29	 

     

    

 

8.8         Contributed
Business Property. Notwithstanding any provision to the contrary in this Agreement, income, gain, loss, and deduction with
respect to property contributed to the Company by a Member shall be shared among the Members so as to take account of the variation
between the basis of the property to the Company and its FMV at the time of contribution in accordance with Section 704(c) of
the Code and the Treasury Regulations thereunder, or any successor provisions thereto. Prior to a subsequent round of equity funding,
or to any other event enumerated in Treas. Reg. § 1.704-1(b)(2)(iv)(f), the Company shall revalue its assets pursuant to
Treas. Reg. § 1.704-1(b)(2)(iv)(f) and allocate such unrealized Profits and Losses of the Company pursuant to Sections 8.3(c)
and (d) as if there were a Liquidation Event. For purposes of Treas. Reg. § 1.704-3, the Management Committee shall consult
with the Company’s accountants and use such method of allocations which allocates tax losses equal to “book”
Losses, to the maximum extent possible, with respect to the Preferred Members and Members admitted in subsequent rounds of financing.

 

8.9         Required
Amendment. The allocations set forth herein shall be amended as may be required from time to time as may be necessary to comply
with the Code and the Treasury Regulations as the same shall be amended after the Effective Date.

 

ARTICLE IX

DISSOLUTION AND LIQUIDATION

 

9.1         Dissolution.

 

(a)          The
withdrawal, expulsion, bankruptcy or dissolution of any Member or the occurrence of any other event that terminates the continued
membership of any Member shall not cause the dissolution of the Company or its affairs to be wound up, and upon the occurrence
of any such event, the Company shall be continued without dissolution.

 

(b)          Upon
the dissolution of the Company in accordance with this Article IX, the Management Committee or, in the event there is then
no Manager, a liquidating agent selected by a Supermajority of the Members, shall proceed to the orderly liquidation of the Company.
Such persons winding up the Company’s affairs may, in the name of and for and on behalf of the Company, prosecute and defend
suits, whether civil, criminal or administrative, settle and close the Company’s business, dispose of and convey the Company’s
property, discharge the Company’s liabilities and distribute to the Members any remaining assets of the Company in accordance
with Section 8.2.

 

9.2         Distributions
in Kind. In the event of a liquidation and dissolution of the Company, in which the assets of the Company are distributed
to the Members, the intellectual property of the Company including the IP contributed by Savsu shall be Distributed to Savsu as
part of its liquidation. The value of such intellectual property so distributed shall be accounted for as part of Savsu’s
Distribution and shall not be construed as a right to an additional Distribution.

 

9.3         Sale
of Assets of the Company.

 

(a)          As
expeditiously as possible, the Management Committee, or any such trustee or liquidator, shall pay all Company liabilities, establish
the reserves and make the distributions provided for in Section 8.2. Except as otherwise provided in Section 9.2, no Member
shall have the right to demand or receive property other than cash upon liquidation, and the Management Committee, or any such
trustee or liquidator, shall, in any event, have the power to sell Company assets for cash as necessary to provide for the payment
of all Company liabilities and the establishment of reserves.

 

    	 	30	 

     

    

 

(b)          In
connection with the sale by the Company and reduction to cash of its assets, although the Company has no obligation to offer to
sell any property to the Members, any Member or any Affiliate of any Member may bid on and purchase any assets of the Company.
If the Management Committee, or any such trustee or liquidator, determines that an immediate sale of part or all of the Company
assets would cause undue loss to the Members, the Management Committee, or any such trustee or liquidator, may defer liquidation
of and withhold from distribution for a reasonable time any assets of the Company (except those necessary to satisfy the Company’s
current obligations).

 

9.4         Orderly
Liquidation. A reasonable time shall be allowed for the orderly liquidation of the assets of the Company and the discharge
of liabilities to creditors so as to minimize the losses normally attendant upon liquidation.

 

9.5         Statements
on Liquidation. On liquidation, each of the Members shall be furnished promptly with a statement which shall set forth the
assets and liabilities of the Company as at the date of liquidation, and each Member’s share thereof and a final Federal
Partnership Tax Return. Within ninety (90) days following the date of dissolution, the Management Committee, or liquidating agent
if there be one, shall execute and cause to be filed Articles of Dissolution of the Company.

 

ARTICLE X

NO REQUIREMENT TO RESTORE

DEFICIT IN CAPITAL ACCOUNT

 

10.1       No
Requirement to Restore Deficit in Capital Account. Nothing contained in this Agreement shall be construed to require any Member
to restore any deficit in a Capital Account by making any Capital Contributions to the Company.

 

10.2       Provisions
of Agreement Not For Benefit of Any Creditor. None of the provisions of this Agreement shall be construed as existing for
the benefit of any creditor of any of the Members or of the Company, nor shall any such provision be enforceable by any party
not a signatory to this Agreement.

 

ARTICLE XI

BOOKS, RECORDS AND EXPENSES

 

11.1       Books
of Account. At all times during the continuance of the Company, the Management Committee shall keep or cause to be kept true
and complete books of account in which shall be entered fully and accurately each transaction of the Company. Such books shall
be kept on the basis of the Fiscal Year in accordance with the GAAP method of accounting, and shall reflect all Company transactions,
to the extent practicable, in accordance with sound accounting practices.

 

    	 	31	 

     

    

 

11.2         Availability
of Books of Account. All of the books of account referred to in Section 11.1, together with an executed copy of this
Agreement and the Certificate of Formation, and any amendments thereto, shall at all times be maintained by the Company, and shall
be open to the inspection and examination of the Members or their agents, as provided in Section 4.5.

 

11.3         Accounting
Expenses. All out-of-pocket expenses payable to Persons who are not an Affiliate of any Member in connection with the keeping
of the books and records of the Company and the preparation of audited or unaudited financial statements and federal and local
tax and information returns required to implement the provisions of this Agreement or required by any Governmental Authority with
jurisdiction over the Company shall be borne by the Company as an ordinary expense of its business.

 

11.4         Bank
Account. The Company shall maintain its bank deposits in segregated accounts held for the Company’s business. All funds
of the Company shall be promptly deposited in the appropriate segregated account.

 

11.5         Fidelity
Bonds and Insurance. The Company may obtain fidelity bonds with reputable surety companies, covering all persons having access
to the Company’s funds, indemnifying the Company against loss resulting from fraud, theft and dishonest and other wrongful
acts of such persons.

 

ARTICLE XII

AMENDMENTS

 

12.1         Amendments.
Amendments may be made to this Agreement from time to time by the unanimous vote of the Members and the Management Committee.
In making any amendments, there shall be prepared and filed for recordation by the Management Committee such documents and certificates
as shall be required to be prepared and filed.

 

ARTICLE XIII

GENERAL PROVISIONS

 

13.1         Further
Assurances. Each party to this Agreement agrees to execute, acknowledge, deliver, file and record such further certificates,
amendments, instruments and documents, and to do all such other acts and things, as may be required by law or as, in the reasonable
judgment of the Management Committee, may be necessary or advisable to carry out the intent and purpose of this Agreement.

 

13.2         Notices.
Unless otherwise specified in this Agreement, all notices, demands, elections, requests or other communications that any party
to this Agreement may desire or be required to give hereunder shall be in writing and shall be given by hand, by facsimile or
electronic transmission with delivery of an original thereafter by any other method provided by this Section, or by a recognized
international overnight courier service providing confirmation of delivery for next Business day delivery, or depositing the same
in the United States mail, first class postage prepaid, or certified or registered mail, return receipt requested, addressed as
follows:

 

    	 	32	 

     

    

 

(a)          To
the Company, at 160 Sweet Hollow Road, Old Bethpage, New York 11804, attention: Bruce McCormick, President, or at such other address
as may be designated by the Management Committee upon written notice to all of the Members; and

 

(b)          To
the Members at their respective addresses set forth in the Company’s books and records. Each Member shall have the right
to designate another address or change in address by written notice to the Company in the manner prescribed herein.

 

All notices given
pursuant to this Section 13.2 shall be deemed received (i) when actually received if hand delivered and (ii) on the Business
Day of receipt if sent by any other method contemplated by this Section 13.2.

 

13.3       Headings
and Captions. All headings and captions contained in this Agreement and the table of contents hereto are inserted for convenience
only and shall not be deemed a part of this Agreement.

 

13.4       Variance
of Pronouns. All pronouns and all variations thereof shall be deemed to refer to the masculine, feminine or neuter, singular
or plural, as the identity of the person or entity may require.

 

13.5       Partition.
The Members agree that no Member nor any successor in interest to any Member shall have the right, while this Agreement remains
in effect, to have the property of the Company partitioned, or to file a complaint or institute any proceeding at law or in equity
to have the property of the Company partitioned, and each Member, on behalf of itself, its successors, heirs and assigns, waives
any such right.

 

13.6       Invalidity.
Every provision of this Agreement is intended to be severable. The invalidity and unenforceability of any particular provision
of this Agreement in any jurisdiction shall not affect the other provisions, and this Agreement shall be construed in all respects
as if such invalid or unenforceable provision were omitted.

 

13.7       Successors
and Assigns. This Agreement shall be binding upon the parties and their respective successors, executors, administrators,
heirs and permitted legal assigns and shall inure to the benefit of the parties and, except as otherwise provided herein, their
respective successors, executors, administrators, legal, heirs and permitted legal assigns. No Person other than the parties hereto
and their respective successors, executors, administrators, heirs and permitted legal assigns, shall have any rights or claims
under this Agreement.

 

13.8       Power
of Attorney.

 

(a)          Each
Member does irrevocably constitute and appoint the Management Committee, with full power of substitution, as its true and lawful
attorney, in its name, place and stead, to execute, acknowledge, swear to, deliver, record and file, as appropriate and in accordance
with this Agreement: (i) the original Certificate of Formation and all amendments to the Certificate of Formation required or
permitted by law or the provisions of this Agreement, (ii) all certificates and other instruments requiring execution by the Members
or any of them and deemed necessary or advisable by the Management Committee to qualify or continue the Company as a limited liability
company in the jurisdictions where the Company may be conducting its operations, (iii) all instruments, agreements or documents
that the Members so direct and (iv) all conveyances and other instruments deemed necessary or advisable by the Management Committee
to effect the dissolution and termination of the Company in accordance with this Agreement. Nothing contained in this Section
13.8 shall empower the Management Committee to take any action requiring the consent of the Members unless such consent is
first obtained.

 

    	 	33	 

     

    

 

(b)          The
powers of attorney granted pursuant to this Section 13.8 are coupled with an interest and shall be irrevocable and survive
and not be affected by the subsequent death, incapacity, disability, Bankruptcy Event or dissolution of the grantor; may be exercised
by the Management Committee either by signing separately as attorney-in-fact for each Member or by the Management Committee as
attorneys-in-fact for all of them, as shall be applicable; and shall survive the delivery of an assignment by a Member of the
whole or any fraction of its Membership Interest, except that, where the whole of such Member’s Membership Interest has
been assigned or diluted in accordance with this Agreement, the power of attorney of the assignor shall survive the delivery of
such assignment for the sole purpose of enabling the Management Committee to execute, acknowledge, swear to, deliver, record and
file any instrument necessary or appropriate to effect such substitution. In the event of any conflict between this Agreement
and any document, instrument, conveyance or certificate executed or filed by the Management Committee pursuant to such power of
attorney, this Agreement shall control.

 

13.9       Governing
Law. This Agreement shall be construed in accordance in all respects with the laws of the State of Delaware, without regard
to the conflicts of laws provisions thereof.

 

13.10     Jurisdiction.
Any matter arising out of or relating to this Agreement, or the making, performance or interpretation hereof, shall be submitted
to the exclusive jurisdiction of the federal and state courts sitting in the County of Nassau, State of New York. The parties
irrevocably submit to such jurisdiction, agree not to assert any claim or defense that is not personally subject to the jurisdiction
of such courts or that such forum is not convenient or the venue thereof is improper, and consent to service of process in any
action or proceeding by written notice, delivered in the manner provided for in Section 13.2.

 

13.11     Entire
Agreement. This Agreement, together with all Exhibits, Schedules, and Annexes hereto, supersedes all prior agreements among
the parties with respect to the subject matter hereof, including without limitation the LLC Agreement, which is hereby amended
and restated. This Agreement contains the entire agreement among the parties with respect to such subject matter. This instrument
may not be amended, supplemented or discharged, and no provisions hereof may be modified or waived, except expressly by an instrument
in writing signed by the Management Committee and each Member. No waiver of any provision hereof by any party hereto shall be
deemed a waiver by any other party nor shall any such waiver by any party be deemed a continuing waiver of any matter by such
party. No amendment, modification, supplement, discharge or waiver hereof or hereunder shall require the consent of any person
not a party to this Agreement.

 

13.12     Legal
Fees. Each party shall bear its own legal expenses in connection with the negotiation, execution and delivery of this Agreement
and any documents related thereto.

 

    	 	34	 

     

    

 

13.13      No
Third Party Beneficiaries. None of the provisions of this Agreement shall be construed as existing for the benefit of any
party, including any creditor of the Company or any of the Members, not a signatory to this Agreement, nor shall any such provision
be enforceable by any such party.

 

13.14      Counterparts.
This Agreement may be executed in two or more counterparts, and by original, facsimile or PDF (portable document format) signatures,
each of which shall constitute an original and all of which, when taken together, shall constitute one Agreement.

 

13.15      WAIVER
OF JURY TRIAL EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR
COUNTERCLAIM ARISING IN CONNECTION WITH, OUT OF OR OTHERWISE RELATING TO THIS AGREEMENT.

 

13.16      This
Agreement is and shall be effective on and as of the Effective Date.

 

[signature page immediately
follows]

 

    	 	35	 

     

    

 

IN
WITNESS WHEREOF, each of the Company, the Members and the Managers has executed this Agreement as of the Effective
Date.

 

	 	COMPANY:
	 	 
	 	BIOLOGISTEX CCM, LLC
	 	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	MEMBERS:
	 	 
	 	BIOLIFE SOLUTIONS, INC.
	 	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	SAVSU TECHNOLOGIES, LLC
	 	 	 
	 	By:	 
	 	Name:  Dana E. Barnard
	 	Title:  Manager
	 	 
	 	MANAGERS:
	 	 
	 	 
	 	DANA BARNARD
	 	 
	 	 
	 	MICHAEL RICE
	 	 
	 	 
	 	BRUCE McCORMICK

 

[Signature page to Amended and Restated
Operating Agreement – biologistex CCM, LLC]

 

     

     

    

 

SCHEDULE A

 

MEMBERS and CAPITAL CONTRIBUTIONS 

 

(as of the Effective Date)

 

	NAME
    of Member	 	capital

    contributions	 
	BIOLIFE SOLUTIONS, INC.	 	$	 	 
	SAVSU TECHNOLOGIES, LLC	 	$	 	 
	Total	 	$	 	 

 

The Profits Percentages and the Capital
Percentages of the Members are set forth in Section 1.1 of the Agreement.

 

     

     

    

 

SCHEDULE
B

 

LIST OF THE BIOLIFE COPYRIGHTS

 

The BioLife Copyrights
are as follows:

 

[SPECIFY THE CLOUD-BASED SOFTWARE APPLICATIONS
AND WEB PLATFORMS OWNED BY BIOLIFE]

 

     

     

    

 

SCHEDULE C

 

LIST OF THE SAVSU PATENTS

 

The Savsu Patents
are as follows:

 

[LIST THE PATENT REGISTRATIONS
AND ANY PATENTS PENDING OWNED BY SAVSU]Exhibit 10.33

 

SERVICES AGREEMENT

 

This Services
Agreement (this “Agreement”) is made and entered into effective as of December 31, 2016 (the “Effective
Date”), by and between BioLife Solutions, Inc., a Delaware corporation (“BioLife”),
and bioLogistex CCM, LLC, a Delaware limited liability company (“Client”). Each of BioLife
and Client may be referred to herein individually as a “Party”, and collectively as the “Parties”.

 

WHEREAS, pursuant
to that certain Contribution Agreement, dated effective as the Effective Date (the “Contribution Agreement”),
by and among the Parties and Savsu Technologies, LLC, a Delaware limited liability company, BioLife is making certain contributions
to Client subject to the terms and conditions set forth therein, including the entrance by the Parties into this Agreement, which
is a material inducement for BioLife entering into and consummating the transactions contemplated by the Contribution Agreement;
and

 

WHEREAS, Client desires
to obtain from BioLife, and BioLife is willing to provide to Client, certain sales and marketing services as set forth in this
Agreement to or on behalf of Client in accordance with the terms and conditions of this Agreement.

 

NOW, THEREFORE, in
consideration of the foregoing premises and the mutual covenants, conditions and provisions contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

ARTICLE
I. SERVICES

 

1.1.          Services.
Subject to the terms and conditions of this Agreement, BioLife will provide, or cause to be provided to Client and its subsidiaries,
the sales and marketing services set forth on Schedule A hereto (collectively, the “Services”).
Client acknowledges that, except as otherwise consented to by BioLife in writing, the Services shall be provided only with respect
to Client or its subsidiaries, and Client shall not be entitled to performance of any Service for the benefit of any person other
than Client or its subsidiaries without the written consent of BioLife. Any or all of the Services may be modified in any respect
upon mutual written agreement of BioLife and Client.

 

1.2.          Employee
Cooperation. BioLife will cause its employees providing the Services (“BioLife Employees”) to cooperate
with the employees of Client and its subsidiaries (“Client Employees”), but BioLife will not have any
other duty or obligation with respect to Client Employees (except for any Services that are expressly provided to or on behalf
of Client Employees pursuant to Schedule A). Client shall, and shall cause its subsidiaries and the Client Employees to,
cooperate with the provision by or on behalf of BioLife of the Services hereunder, including providing any information or documentation
necessary or appropriate for the provision of the Services or the invoicing of the Monthly Fee, Commissions and Expenses (each
term as defined below) and complying with applicable law and the terms of any thirdparty agreements used by BioLife in providing
the Services.

 

1.3.          Standard
of Performance; Limited Warranty. BioLife will perform, or will cause to be performed, the Services (a) in a commercially reasonable
manner and level of service, and (b) in all material respects in accordance with applicable laws. Except
as provided in this Section 1.3, BioLife does not make any warranty concerning the Services, and the warranty in this Section 1.3
is in lieu of, and BioLife hereby disclaims, any and all other warranties, express or implied, including any warranty or merchantability
or fitness for a particular purpose.

 

     

     

    

 

ARTICLE
II. charges

 

2.1.        Monthly
Fee. On each of (i) the first business day after Effective Date, (ii) February 1, 2017 and (iii) the first day of each of the
next ten (10) calendar months thereafter during the Term (as defined below), Client shall pay to BioLife the amount of $10,000
(the “Monthly Fee”), by wire transfer of immediately available funds to an account specified in writing
by BioLife to Client, which Monthly Fee shall be in addition to any Commissions, Expenses or other amounts payable under this Agreement.

 

2.2.        Commissions.

 

(a)          In
exchange for causing the provision of the Services hereunder, BioLife will be entitled to receive from Client a commission (the
“Commissions”) during the first three (3) years of the Term (the “Initial Term”)
equal to twenty percent (20%) of the BioLife Customer Revenue. For purposes of this Agreement, “BioLife Customer Revenue”
shall mean the gross revenues of Client or its subsidiaries from any customer account resulting from a BioLife generated marketing
lead and/or sales activity (a “BioLife Customer Account”) (including any contracts or agreements generated
with such customer account and any renewals or extensions thereof). With respect to any customer account of Client or its subsidiaries
for which both BioLife and Client had significant involvement in its generation (which for the avoidance of doubt will exclude
any Persons who are or have been customers of BioLife or its subsidiaries at or prior to the Effective Date), such customer account
will be a BioLife Customer Account, but the Parties will negotiate reasonably and in good faith a written agreement by the Parties
providing that the BioLife Customer Revenue from such BioLife Customer Account will be reduced by a percentage (as reasonably agreed
by the Parties acting in good faith) attributable to Client’s portion of such joint efforts with respect to such BioLife
Customer Account generation. For any portion of the Term (as defined below) after the Initial Term, the Commissions shall instead
be equal to ten percent (10%) of the BioLife Customer Revenue. The Commissions shall be calculated quarterly in arrears.

 

(b)          On
the fifteenth (15th) day after each calendar quarter, Client shall (i) deliver a written statement to BioLife (the “Commission
Statement”) setting forth its good faith determination of the Commissions owed to BioLife for the immediately preceding
calendar quarter, along with a line item description of the gross sales by customer for Client and its subsidiaries, showing the
dates and amounts thereof, for the immediately preceding calendar quarter, and specifying each BioLife Customer Account and the
applicable BioLife Customer Revenue, all in sufficient detail to verify its determination of the amount of Commissions owed to
BioLife for such calendar quarter, and (ii) pay to BioLife an amount equal to the Commissions for the immediately preceding calendar
quarter as set forth in the Commission Statement.

 

(c)          BioLife
will have a period of forty-five (45) days after its receipt of a Commission Statement to dispute the determination of the Commissions
for the calendar quarter set forth therein. In connection with its review of the Commission Statement, Client will, and will cause
its representatives to, provide BioLife and its representatives with reasonable access to the books and records, personnel and
properties of Client and its subsidiaries, and any other information reasonably requested by BioLife or its representatives in
connection with such review. In the event that BioLife provides Client with a written notice (an “Objection Notice”)
during such forty-five (45) day period objecting to the determination of the Commissions for the applicable calendar quarter set
forth in the Commission Statement, including any determination of whether any customer account is a BioLife Customer Account or
whether the revenue from such customer is BioLife Customer Revenue, BioLife and Client shall meet and attempt in good faith to
resolve such objections for a period of twenty (20) days after the delivery of the Objection Notice. In the event that the Parties
fail to come to agreement during such twenty (20) day period, either Party may resolve such dispute in accordance with the dispute
resolution procedure as set forth in Section 5.9. If BioLife does not provide an Objection Notice within forty-five (45) days after
its receipt of a Commission Statement, then except in the case of fraud on the part of Client or its representatives, the Commission
Statement shall be deemed to be final and binding on the Parties with respect to the determination of the Commissions for the calendar
quarter covered thereunder.

 

    	 	2	 

     

    

 

(d)          During
the Term and, if applicable, any Tail Period, Client will use its commercially reasonable efforts to ensure that it has sufficient
inventory available, provides quality customer warranty service and provides other services as reasonably necessary or appropriate
to support the sales by Client and its subsidiaries to BioLife Customer Accounts during such periods.

 

2.3.        Expenses.
In addition to the payment of the Monthly Fee and the Commissions, Client will promptly reimburse BioLife for all reasonable direct
costs and expenses incurred by or on behalf BioLife in connection with the performance of the Services to the extent pre-approved
by Client (“Expenses”). BioLife shall invoice Client for all Expenses for each calendar month or any
portion thereof, as applicable, within thirty (30) days following the end of such calendar month; provided, that any failure
by BioLife to provide an invoice within such time period shall not relieve Client of its obligation to pay an invoice provided
or otherwise received after such date. Within thirty (30) days following receipt of an invoice, Client will pay or cause to be
paid to BioLife, by wire transfer of immediately available funds to an account specified in writing by BioLife to Client, and without
set off, the Expenses contained in such invoice.

 

2.4.        Default.
Without limiting any other rights or remedies of BioLife under this Agreement or applicable law, if Client fails to pay any amounts
owed to BioLife hereunder when due, interest will accrue on the amount payable thereunder at a per annum rate equal to the prime
rate of interest (as published in the Wall Street Journal on the due date of such invoice) plus three percent (3%), compounded
monthly.

 

2.5.        Audit
Rights. Without limiting Section 2.2(c), BioLife shall have the right during the Term and for a period of one (1) year thereafter
(unless there is a Tail Period (as defined below), in which case such right shall continue until one (1) year after the end of
the Tail Period), upon its reasonable request, to, directly or indirectly through BioLife’s representatives, audit the books,
records, files and facilities of Client and its subsidiaries relating to its sales and marketing activities for transactions that
took place in the immediately preceding six (6) calendar quarters; provided, that BioLife and its representatives will use their
commercially reasonable efforts during such audit not to unreasonably disturb the businesses of Client and its subsidiaries. Unless
otherwise consented to by Client, BioLife may conduct any audit under this Section 2.5 at any time during regular business hours
and no more frequently than semi-annually.

 

ARTICLE
III. TERM AND TERMINATION

 

3.1.        Term.
This Agreement will begin effective as of the Effective Date and continue indefinitely unless terminated in accordance with Section
3.2 below (the “Term”).

 

3.2.        Termination
of Agreement. This Agreement may be terminated as follows:

 

(a)          the
Parties may terminate this Agreement at any time by mutual written agreement;

 

(b)          beginning
ninety (90) days prior to the end of the Initial Term, either Party may terminate this Agreement for any reason or no reason after
giving ninety (90) days’ prior written notice to the other Party of such termination;

 

    	 	3	 

     

    

 

(c)          Client
may terminate this Agreement with ninety (90) days’ prior written notice to BioLife in the event that any of the following
occurs: (i) both of Michael Rice and Jim Mathers are no longer officers, employees or independent contractors of BioLife or any
of its subsidiaries; (ii) BioLife sells or transfers (other than an affiliate of BioLife) all of the equity interests that it owns
in Client; or (iii) there is a Change of Control (as defined below) of BioLife;

 

(d)          BioLife
may terminate this Agreement with ninety (90) days’ prior written notice to Client in the event that either of the following
occurs: (i) Savsu sells or transfers (other than an affiliate of Savsu) all of the equity interests that it owns in Client; or
(ii) there is a Change of Control of Savsu; and

 

(e)          either
Party may terminate this Agreement upon written notice to the other Party if the other Party: (i) has violated or breached this
Agreement in any material respect and such violation or breach has not been cured within thirty (30) days after receipt of written
notice thereof by such violating or breaching Party; or (ii) is adjudicated insolvent and/or bankrupt, a receiver or trustee is
appointed for such other Party or its property, a petition for reorganization or arrangement under any bankruptcy or insolvency
law is approved for such other Party or its property or such other Party files a voluntary petition in bankruptcy or consents to
the appointment of a receiver or trustee.

 

For purposes of this
Agreement, a “Change of Control” with respect to any person means the occurrence of any of the following:
(A) a merger, consolidation, corporation reorganization or other business combination where upon consummation of the transaction,
shareholders of such person immediately prior to the consummation of the transaction will hold less than a majority of the aggregate
voting power of the equity securities of such person or the successor entity, (B) the sale or transfer (other than to an affiliate
of such person) of all or substantially all of the assets of such person and its subsidiaries, taken as a whole, in one transaction
or a combination or series of related transactions, or (C) the sale or transfer of a majority of the voting power of the equity
interests of such person, in one transaction or a combination or series of related transactions.

 

3.3.        Effect
of Termination.

 

(a)          The
Parties’ obligations under Sections 1.2 and 1.3, Articles II, IV, V and VI and this Section 3.3 will survive the termination
of this Agreement. Subject to the other provisions of this Agreement, no Party shall be relieved of liability for any violation
or breach of this Agreement by such Party prior to the termination of this Agreement.

 

(b)          Notwithstanding
anything to the contrary contained herein, in the event that either (i) Client terminates this Agreement pursuant to Section 3.2(b)
or 3.2(c) or (ii) BioLife terminates this Agreement pursuant to Section 3.2(d) or 3.2(e), then for a period of twelve (12) months
following such termination (the “Tail Period”), BioLife will be entitled to receive Commissions equal
to ten percent (10%) of the BioLife Customer Revenue during the Tail Period. The Commissions during the Tail Period shall be calculated
quarterly in arrears, and determined and paid using the procedures set forth in Sections 2.2(b) and 2.2(c).

 

ARTICLE
IV. LIMITATION OF LIABILITY; INDEMNIFICATION

 

4.1.        Limitation
of Liability. Notwithstanding anything to the contrary contained herein, including Sections 1.3 and 4.2:

 

    	 	4	 

     

    

 

(a)          BioLife
shall have no responsibility or liability to Client or its subsidiaries in connection with the provision of the Services except
to the extent caused by the gross negligence, willful misconduct or fraud of BioLife or its affiliates or their respective officers,
directors or employees in providing the Services; provided, that if BioLife fails to cause any of the Services to be provided
in accordance with the requirements of Section 1.3, BioLife shall be required to use commercially reasonable efforts to either
correct errors so that such Services, as corrected, satisfy the requirements of Section 1.3 or have such Services re-performed
properly in accordance with requirements of Section 1.3, in either case, at no additional cost or expense to Client or its subsidiaries.
If Client observes any nonconformance with the Service, BioLife must be promptly notified, allowing for necessary corrections.

 

(b)          The
maximum liability of BioLife and its representatives to Client or its representatives or any Client Indemnitee for Losses for any
and all causes whatsoever, and Client’s maximum remedy, regardless of the form of action, whether in contract, tort or otherwise,
shall be limited to the amount of Commissions received by BioLife under this Agreement during the twelve (12) month period preceding
the event giving rise to the claim, suit or other legal proceeding.

 

(c)          In
no event shall BioLife or its representatives be liable to Client or its representatives or any Client Indemnitee for any lost
data, lost profits, business interruption or for any indirect, incidental, special, consequential, exemplary or punitive damages
arising out of or relating to the Services (except to the extent that any such damages are actually awarded to a third party under
a Third Party Claim for which BioLife is required to provided indemnification under Section 4.2(a)), even if Client or its representatives
or other Client Indemnitee has been advised of the possibility of such damages, and notwithstanding the failure of essential purpose
of any limited remedy.

 

4.2.        Indemnification.

 

(a)          Subject
to Section 4.1 and this Section 4.2, BioLife shall indemnify Client and its successors and assigns (collectively, the “Client
Indemnitees”) in respect of, and defend and hold them harmless from and against, any and all claims, charges, actions,
suits, proceedings, costs of investigation, judgments, liens, liabilities, losses, damages, deficiencies, taxes, interest, dues,
penalties, fines, amounts paid in settlement and costs and expenses (including court costs and reasonable attorneys’ or other
professionals’ fees and expenses) (collectively, “Losses”) suffered, incurred or sustained by a
Client Indemnitee to the extent caused by or resulting from (i) the gross negligence, willful misconduct or fraud of BioLife or
its affiliates or their respective officers, directors or employees in connection with the provision of Services under this Agreement
or (ii) a breach by BioLife of this Agreement other than in connection with the provision of Services.

 

(b)          Subject
to Section 4.1 and this Section 4.2, Client shall indemnify BioLife and its successors and assigns (collectively, the “BioLife
Indemnitees”, and any Client Indemnitee or BioLife Indemnitee, an “Indemnitee”) in respect
of, and defend and hold them harmless from and against, any and all Losses suffered, incurred or sustained by a BioLife Indemnitee
(i) to the extent caused by or resulting from a breach by Client of this Agreement or (ii) in connection with this Agreement or
the Services provided hereunder except to the extent caused by or resulting from the gross negligence, willful misconduct or fraud
of BioLife or its affiliates or their respective officers, directors or employees in connection with the provision of Services
under this Agreement.

 

(c)          The
amount of any Losses for which indemnification is provided under this Section 4.2 will be computed net of any insurance proceeds
or other amounts under indemnification or contribution agreements with unaffiliated third parties actually received by an Indemnitee
on account of such Losses. If the amount of any indemnifiable Losses, at any time following the payment of an indemnification obligation,
is offset or reduced by the payment of any insurance proceeds or third party indemnification or contribution proceeds, the amount
of such insurance proceeds or third party indemnification or contribution proceeds, less any costs, expenses, premiums or taxes
incurred in connection therewith (including any future increase in insurance premiums, retroactive premiums, costs associated with
any loss of insurance and replacement thereof or self-insured component of such insurance coverage) shall be promptly repaid to
the Indemnitor (as defined in Section 4.2(e) below).

 

    	 	5	 

     

    

 

(d)          Subject
to Section 4.1, and except for claims for specific performance, injunctive relief or other equitable remedies, the Indemnitees’
rights to indemnification as set forth in this Section 4.2 will be their exclusive remedy with respect to any Losses arising out
of the matters covered by this Agreement other than to terminate this Agreement as set forth in Article III.

 

(e)          In
the event any claim in respect of which an Indemnitee might seek indemnity under this Section 4.2 is asserted against or sought
to be collected from such Indemnitee by a third person (a “Third Party Claim”), the Indemnitee shall
promptly deliver written notice of such Third Party Claim (a “Claim Notice”) to the Party against whom
indemnification is sought under this Section 4.2 (the “Indemnitor”), which Claim Notice must include
a copy of all papers served, if any, and specifying the nature of and basis for such Third Party Claim and for the Indemnitee’s
claim against the Indemnitor under this Section 4.2, together with the amount or, if not then reasonably determinable, the estimated
amount (which estimate will not be conclusive of the final amount for which the Indemnitor shall be responsible with respect to
such Third Party Claim), determined in good faith, of the Loss arising from such Third Party Claim; provided, that the failure
of the Indemnitee to give timely notice of any such Third Party Claim will not relieve the Indemnitor of its indemnification obligations
hereunder except to the extent that such failure has actually prejudiced the Indemnitor. The Indemnitor shall have the right to
control the defense of such Third Party Claim at its sole cost and expense, including the right to settle such Third Party Claim,
so long as the Indemnitor (i) notifies the Indemnitee within thirty (30) days from its receipt of a Claim Notice that it elects
to assume such defense and that it is required to provide indemnification to the Indemnitee with respect to such Third Party Claim
and (ii) provides the Indemnitee with reasonably sufficient evidence of its ability to satisfy such Third Party Claim in full along
with all other outstanding Third Party Claims; provided, that the Indemnitor may compromise or settle such Third Party Claim
only with the consent of the Indemnitee, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding
the foregoing, the Indemnitor shall not have the right to assume or control the defense of any Third Party Claim if at any time
prior to, during or subsequent to the Indemnitor’s delivery of notice of its assumption of the defense of a Third Party Claim,
representation of both the Indemnitee and the Indemnitor by the same counsel would be prohibited by rules or regulations governing
the professional conduct of such counsel due to actual or potential differing interests between them. If the Indemnitor has assumed
the defense of a Third Party Claim in accordance with this Section 4.2(e): (A) the Indemnitee shall cooperate with the Indemnitor
and its counsel in contesting any Third Party Claim, including in making any counterclaim against the person asserting the Third
Party Claim, or any cross-complaint against any person (other than the Indemnitor or any of its affiliates or any affiliate of
the Indemnitee); and (B) the Indemnitee may, at its sole cost and expense, retain separate counsel to participate in, but not control,
any defense or settlement of any Third Party Claim. In the event that the Indemnitor does not elect to assume control of the Third
Party Claim or otherwise is not entitled to control such Third Party Claim in accordance with this Section 4.2(e), the Indemnitee
may control the defense of such Third Party Claim and seek indemnification as permitted by this Article IV with respect to such
Third Party Claim. The Parties (and any other Indemnitee) shall cooperate with each other in all reasonable respects in connection
with the defense of any Third Party Claim, including making available records relating to such Third Party Claim and furnishing,
without expense (other than reimbursement of reasonable, documented, out-of-pocket expenses) to the defending party, employees
and agents of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third Party Claim.
Notwithstanding any other provision of this Section 4.2, the Indemnitor shall not have indemnification obligations with respect
to any settlement or compromise of any Third Party Claim entered into by an Indemnitee without the prior written consent of the
Indemnitor (which consent shall not be unreasonably withheld, delayed or conditioned).

 

    	 	6	 

     

    

 

(f)          In
the event any Indemnitee should have a claim under this Section 4.2 against any Indemnitor that does not involve a Third Party
Claim, the Indemnitee shall promptly deliver written notice of such claim to the Indemnitor, which notice shall specify the nature
of and basis for such claim, together with the amount or, if not then reasonably determinable, the estimated amount (which estimate
will not be conclusive of the final amount for which the Indemnitor shall be responsible with respect to such claim), determined
in good faith, of the Loss arising from such claim; provided, that the failure of the Indemnitee to give timely notice of
any such claim will not relieve the Indemnitor of its indemnification obligations hereunder except to the extent that such failure
has actually prejudiced the Indemnitor.

 

4.3.        Force
Majeure. BioLife shall not be required to provide any Service and shall not be liable to Client or it subsidiaries for failure
to perform or delays in performing any part of the Services if such failure or delay results from an act of god, war, terrorism,
revolt, revolution, sabotage, actions of a governmental authority, laws, embargo, fire, strike, other labor trouble or any other
cause or circumstance reasonably beyond the control of BioLife (any of the foregoing, a “Force Majeure”).
Upon the occurrence of any Force Majeure which results in, or will result in, delay or failure to perform according to the terms
of this Agreement, BioLife will promptly give notice to Client of such occurrence and the effect and/or anticipated effect of such
occurrence. BioLife will use its commercially reasonable efforts to minimize disruptions in its performance, to resume performance
of its obligations under this Agreement as soon as reasonably practicable and to assist Client in obtaining, at its sole expense,
an alternative source for the affected Services.

 

ARTICLE
V. MISCELLANEOUS

 

5.1.        Confidentiality.
Client shall, and shall cause its respective representatives to: (a) treat and hold in strict confidence any BioLife Confidential
Information, and not use for any purpose (other than in connection with this Agreement), nor directly or indirectly disclose, distribute,
publish, disseminate or otherwise make available to any third party any of the BioLife Confidential Information without the prior
written consent of the BioLife; (b) in the event the Client or its representatives becomes legally compelled to disclose any BioLife
Confidential Information, to provide the BioLife with prompt written notice of such requirement so that BioLife or an affiliate
thereof may seek a protective order or other remedy or so that BioLife may waive compliance with this Section 5.1; and (c) in the
event that such protective order or other remedy is not obtained, or BioLife waives compliance with this Section 5.1, to furnish
only that portion of such BioLife Confidential Information which is legally required to be provided as advised in writing by outside
counsel and to exercise their commercially reasonable efforts to obtain assurances that confidential treatment will be accorded
such BioLife Confidential Information. As used in this Agreement, “BioLife Confidential Information”
means the terms and provisions of this Agreement and any information concerning the Services, the business or operations of BioLife,
or, to the extent disclosed in connection with this Agreement or the transactions contemplated hereby, all confidential and or
proprietary information of BioLife, including trade secrets, customer lists, details of customer or consultant contracts, pricing
policies, operational methods and marketing plans or strategies, and any information disclosed to BioLife by third parties to the
extent that it has an obligation of confidentiality in connection therewith; provided, however, that BioLife Confidential Information
shall not include any information which, at the time of disclosure, is generally available publicly and was not disclosed in breach
of this Agreement by Client or its representatives.

 

    	 	7	 

     

    

 

5.2.         Relationship
of Parties. BioLife will (a) be deemed to be an independent contractor with respect to the provision of Services hereunder,
(b) not be considered (nor will any of its directors, officers, employees, contractors or agents be considered) an employee, commercial
representative, partner, franchisee or joint venturer of Client as a result of or in connection with this Agreement or the provision
of the Services hereunder and (c) have no duties or obligations in connection with this Agreement beyond those expressly provided
in this Agreement with respect to the provision of Services. No Party will have as a result of this Agreement any authority, absent
express written permission from the other Party, to enter into any agreement, assume or create any obligations or liabilities,
or make representations on behalf of the other Party.

 

5.3.         Interpretation.
When a reference is made in this Agreement to Articles, Sections or Schedules, such reference will be to an Article or Section
of or Schedule to this Agreement unless otherwise indicated. The headings contained in this Agreement are for reference purposes
only and will not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,”
“includes” or “including” are used in this Agreement, they will be deemed to be followed by the words “without
limitation.” The words “hereof,” “herein” and “hereunder” and words of similar import
when used in this Agreement will refer to this Agreement as a whole and not to any particular provision of this Agreement. Unless
the context otherwise requires, (i) words in the singular include the plural and vice versa and (ii) the use in this Agreement
of a pronoun in reference to a person includes the masculine, feminine or neuter, as the context may require. All Schedules hereto
will be deemed part of this Agreement and included in any reference to this Agreement. As used in this Agreement, the term (i)
“business day” shall mean any day other than a Saturday, a Sunday or a day on which banks in New York, New York are
authorized or obligated by law or executive order to close, (ii) “person” means any natural person, corporation, limited
liability company, partnership, trust, joint venture or other business entity, unincorporated association, organization or enterprise
or governmental entity, (iii) “affiliate” means, as applied to any person, any other person directly or indirectly
controlling, controlled by or under direct or indirect common control with, such person, where “control” (including
with correlative meanings, the terms “controlling,” “controlled by” and “under common control with”),
as applied to any person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of such person, whether through the ownership of voting securities, by contract or otherwise, and (iv) “representatives”
means, as to any person, such person’s affiliates and the managers, directors, officers, employees, agents and advisors (including
financial advisors, counsel and accountants) of such person or its affiliates. For purposes of this Agreement, each Party shall
not be treated as an affiliate or representative of the other Party. This Agreement will not be interpreted or construed to require
any Party to take any action, or fail to take any action, if to do so would violate any applicable law.

 

5.4.         Joint
Participation. Both Parties have participated in negotiating and drafting this Agreement. In the event that an ambiguity or
a question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by both Parties, and no presumption
or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement.

 

5.5.         Amendment:
Waiver. This Agreement may be amended, modified or supplemented only by the written agreement of the Parties hereto. Except
as otherwise provided in this Agreement, the failure by any Party to comply with any obligation, covenant, agreement or condition
under this Agreement may be waived by the Party entitled to the benefit thereof only by a written instrument signed by the Party
granting such waiver, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or
condition will not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. The failure of any Party
to enforce at any time any of the provisions of this Agreement will in no way be construed to be a waiver of any such provision,
or in any way to affect the validity of this Agreement or any part hereof or the right of any Party hereafter to enforce each and
every such provision. No waiver of any breach of such provisions will be held to be a waiver of any other or subsequent breach.

 

    	 	8	 

     

    

 

5.6.         Notices.
All notices, approvals and consents provided for herein shall be in writing and be given in person, by nationally recognized overnight
courier, by U.S. mail or by means of facsimile or other means of electronic document delivery, and shall become effective: (a)
on delivery if given in person; (b) on the date of affirmative confirmation of receipt if sent by facsimile or other means of electronic
document delivery; (c) one (1) business day after delivery to the overnight service; or (d) three (3) business days after being
mailed, with proper postage and documentation, for first-class registered or certified mail, prepaid, in any case, to the address
of the Party underneath the signature of such Party on the signature page hereto, as such address may be modified by written notice
of such Party in accordance with the requirements of this Section 5.6.

 

5.7.         Successors
and Assigns; Third Party Beneficiaries. This Agreement will be binding upon and will inure to the benefit of the Parties hereto
and their respective successors and permitted assigns. No Party may assign this Agreement, or any of its rights or liabilities
hereunder, without the prior written consent of the other Party hereto, and any attempt to make any such assignment without such
consent will be null and void. Nothing in this Agreement is intended to confer on any person other than the Parties hereto or their
respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

5.8.         Severability.
In the event that any provision of this Agreement or the application thereof, becomes or is declared by a court of competent jurisdiction
to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application
of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the Parties hereto.
The Parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision
that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.

 

5.9.         Dispute
Resolution. Any and all disputes, controversies and claims (other than applications for a temporary restraining order, preliminary
injunction, permanent injunction or other equitable relief or an application for enforcement of a resolution under this Section
5.9) arising out of, related to, or in connection with this Agreement (a “Dispute”) shall be governed
by this Section 5.9. The Parties agrees that any Dispute will be submitted to and determined exclusively by binding arbitration
in Nassau County, New York, before a single arbitrator from the Judicial Arbitration Mediation Service (“JAMS”)
selected in accordance with the commercial arbitration rules of JAMS then in effect (the “Rules”), which
arbitrator shall be a commercial lawyer with substantial experience arbitrating disputes under commercial contracts. Such arbitration
shall be conducted in accordance with such Rules and this Agreement, and judgment on the arbitration award may be entered in any
court having jurisdiction over the subject matter of controversy. To the extent that the Rules and this Agreement are in conflict,
the terms of this Agreement shall control. The arbitrator shall decide the Dispute in accordance with the substantive law of the
State of New York. Each Party shall submit a proposal for resolution of the Dispute to the arbitrator within thirty (30) days after
confirmation of the appointment of the arbitrator. The arbitrator shall have the power to order any Party to do, or to refrain
from doing, anything consistent with this Agreement and applicable law, including to perform its contractual obligation(s); provided,
that the arbitrator shall be limited to ordering pursuant to the foregoing power (and, for the avoidance of doubt, shall order)
the relevant Party (or Parties, as applicable) to comply with only one or the other of the proposals. The arbitrator’s award
shall be in writing and shall include a reasonable explanation of the arbitrator’s reason(s) for selecting one or the other
proposal. Each Party shall pay for its own costs and attorneys’ fees, if any. The fees, costs and expenses of the arbitrator
will be borne by the non-prevailing party. Notwithstanding the foregoing in this Section 5.9, BioLife shall have the right in accordance
with Section 5.10 to seek injunctive or other equitable action in any court of competent jurisdiction in connection with any actual
or alleged breach of this Agreement.

 

    	 	9	 

     

    

 

5.10.       Governing
Law; Jurisdiction; Waiver of Jury Trial. This Agreement will be governed by and
construed in accordance with the internal laws of the State of New York, without regard to any applicable conflict of laws principles.
Subject to Section 5.9, each Party irrevocably agrees that any legal suit, action or proceeding or counter-claim with respect to
this Agreement, the transactions contemplated hereby, any provision hereof, the breach, performance, validity or invalidity hereof
or for recognition and enforcement of any judgment in respect hereof brought by another Party hereto or its successors or permitted
assigns (a “Proceeding”) may be brought and determined in any federal or state court located in Nassau
County, New York (and any appellate courts thereof), and each Party hereby (a) irrevocably submits with regard to any such action
or proceeding for itself and in respect to its property, generally and unconditionally, to the exclusive jurisdiction of the aforesaid
courts, (b) agrees that service of any process, summons, notice or document by U.S. registered mail to such party’s address
in accordance with Section 5.6 shall be effective service of process for any Proceeding with respect to any matters to which it
has submitted to jurisdiction in this Section 5.10, and (c) waives and covenants not to assert or plead, by way of motion, as a
defense or otherwise, in any such Proceeding, any claim that it is not subject personally to the jurisdiction of such court, that
such Proceeding is brought in an inconvenient forum, that the venue of such Proceeding is improper or that this Agreement or the
subject matter hereof may not be enforced in or by such court, and hereby agrees not to challenge such jurisdiction or venue by
reason of any offsets or counterclaims in any such Proceeding. Each Party knowingly and
irrevocably waives any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the
transactions contemplated hereby.

 

5.11.       Entire
Agreement. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written
and oral, among the Parties with respect to the subject matter of this Agreement. If there is any conflict or inconsistency between
the terms and conditions set forth in the main body of this Agreement and the Schedules hereto, the provisions of the Schedules
shall control with respect to the rights and obligations of the Parties regarding the Services.

 

5.12.       Counterparts.
This Agreement may be executed in one or more counterparts (including by facsimile or other electronic document delivery), each
of which will be deemed an original, but all of which together will constitute one and the same instrument.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK; SIGNATURE PAGE FOLLOWS]

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Services Agreement to be executed by their respective officers thereunto duly authorized, as
of the date first written above.

 

	BIOLIFE SOLUTIONS, INC.	 
	 	 	 
	By: 	 	 
	Name:  Roderick de Greef	 
	Title:  Chief Financial Officer	 

 

	Address for Notice:	with a copy (which shall not constitute notice) to:
	 	 
	BioLife Solutions, Inc. 

3303 Monte Villa Parkway, Suite 310

Bothell, Washington 98021

Attention:  Michael Rice, CEO

Telephone No.:  (425) 402-1400

Email:  mrice@BioLifeSolutions.com	
        Ellenoff Grossman & Schole LLP

        1345 Avenue of the Americas, 11th Floor

        New York, New York 10105

        Attn: Sarah Williams, Esq.

                   Matthew A. Gray, Esq.

        Telephone No: (212) 370-1300

        Fax: (212) 370-7889

        Email: swilliams@egsllp.com

                   mgray@egsllp.com

 

	BIOLOGISTEX CCM, LLC	 
	 	 	 
	By: 	 	 
	Name:  Michael Rice	 
	Title:  President	 

 

	Address for Notice	With a copy (which shall not constitute notice) to:
	 	 
	
        bioLogistex CCM, LLC

        160 Sweet Hollow Road

        Old Bethpage, NY 11804

        Attention: Bruce McCormick, President

        Telephone No.: (516) 752-7882

        Facsimile No.: (516) 752-7951

        Email: b.mccormick@savsu.com
	Meltzer, Lippe, Goldstein & Breitstone, LLP

190 Willis Avenue

Mineola, NY 11501

Attention:  Ira R. Halperin, Esq.

Telephone No.:  (516) 747-0300

Facsimile No.:  (516) 747-0653

Email:  ihalperin@meltzerlippe.com

 

[Signature Page to Services Agreement]

 

     

     

    

 

Schedule A

Services

 

Description of Service

 

		1.	Customer acquisition and other sales activities targeting
evo opportunities in the biobanking, drug discovery, and regenerative medicine market segments where biopreservation media opportunities
are present (the “BioLife Markets”), to leverage BioLife’s current customer relationships and
ability to offer a portfolio of complementary biopreservation tools including media and evo. Client will market and sell to non-media
market segments such as vaccine storage and shipment.

 

		2.	Marketing and promotion of evo and Client SaaS at biopreservation
media trade shows, with total event costs shared equally by BioLife and Client and with each Party bearing expenses for their
respective personnel attending the event. At Client’s request, marketing and promotion of evo and Client SaaS at non-biopreservation
media trade shows, with total event costs and BioLife personnel costs borne by Client. Notwithstanding the foregoing, BioLife’s
expenses with the respect to the foregoing shall only be reimbursed to the extent pre-approved by Client.

 

		3.	Solely for the 6-month period commencing on the Effective
Date, support of evo customers and prospects engaged before the Effective Date and closed afterward by BioLife in the referenced
BioLife Markets including order fulfillment, customer onboarding and training, ongoing app support, and evo warranty and out of
warranty repairs or replacements for customers that BioLife closed.

 

		4.	Commercial input into ongoing product development efforts
on the evo and Client Saas application as requested by Client.

 

    	 	A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]